South African Medical Research Council (SAMRC)

Annual Performance Plan

2022/23

Date of Tabling

March 2022



Table of Contents

Executiv	ve Authority Statement	i
Account	ting Authority Statement	ii
Stateme	ent by the President of the SAMRC	iv
Official	Sign Off	vi
1	SAMRC Mandate	2
2	Legislative and Other Policy Mandates	2
3	Situational Analysis	. 11
3.1	Introduction	. 11
3.2	External Environmental Analysis	. 12
3.2.1	National Health Research Committee	. 12
3.2.2	National Department of Health	. 12
3.2.3	4th Industrial Revolution	. 14
3.2.4	mRNA Technology Transfer Hub	. 14
3.2.5	COVID-19 and Cancer Vaccine Initiative	. 15
3.3	Internal Environmental Analysis	. 15
3.3.1	Introduction	. 15
3.3.2	Open Science	. 17
3.3.3	Communication	. 17
3.3.4	Research Integrity and Ethics	. 17
3.3.5	SAMRC BOARD	. 18
3.3.6	SAMRC PRESIDENT	. 19
3.3.7	THE EXECUTIVE MANAGEMENT COMMITTEE	. 19
3.3.8	SAMRC LEADERSHIP STRUCTURE	. 19
3.3.9	Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis	. 20
3.3.10	B-BBEE Compliance Performance Information	. 20
4	Human Resource Management	. 22
5	Investing in Human Capital Development and Capacity in Health Care: Bongani Mayosi National Hea Scholars Programme	
6	SAMRC Intramural and Extramural research units, and Platforms	. 27
7	SAMRC Research Centres	. 33
8	Institutional Programme Performance Information	. 35
8.1	Programme 1: Administration	. 35
8.2	Programme 2: Core Research	. 36
8.3	Programme 3: Innovation and Technology	. 38
8.4	Programme 4: Capacity Development	. 40
8.5	Programme 5: Research Translation	. 42
9	Planned performance over the five-year planning period	. 44
9.1	Implementation Plan for Biostatistics Capacity Development in Collaboration with Hasselt University	. 44
9.2	Doctoral scholarships	. 44

9.3	Extramural Research Units	44
9.4	Collaborating Centres for Cancer	44
9.5	TB/HIV Collaborating Centres	44
9.6	Collaborating Centre for Digital Health Innovation	44
9.7	Request for Application (RFAs) for research priorities identified through the strategic planning process and National Priorities.	
9.8	Driving Transformation and Capacity Development.	45
9.9	Funding and Budget Related Issue in key areas of savings and reprioritisation	45
10	Programme Resource Considerations	46
11	Key Risks which may affect achievement of the outcomes	46
12	Public Entity Description:	49
13	Infra-structure Projects	49
14	Public Private Partnerships	49
Annexur	re A: Consolidated Indicators	60
Annexur	re B – SAMRC's Materiality and Significance Framework 2022/23	62
Annexur	re C: Acronyms	65

Executive Authority Statement

The South African Medical Research Council (SAMRC) 2022/23 Annual Performance Plan (APP) is drawn from the 2020/21 – 2024/25 Strategic Plan. This APP takes into account all the relevant policies, legislation and other mandates of for which the South African Medical Research Council is responsible.

The APP accurately reflects the strategic goals and objectives that the South African Medical Research Council will endeavour to achieve over the period 2022/2023.

I hereby endorse this South African Medical Research Council Annual Performance Plan (APP) developed by the Executive Management Committee of the South African Medical Research Council under the guidance of Professor Johnny Mahlangu of the SAMRC Board and the SAMRC CEO and President, Professor Glenda Gray

Dr. MJ Phaahla (MP) Minister of Health

Accounting Authority Statement

The South African Medical Research Council (SAMRC) has just celebrated 50 years of its existence. In this past half a century, this dynamic organisation can be proud of its health research impacts and outcomes including setting the national research agenda, attracting the financial and human resources to conduct relevant and responsive health research, training a diverse cadre of the next generation of researchers and aligning research effort and activities to the health priorities and needs of the country. As a public entity, the SAMRC has been exemplary in many areas of its mandate including excellence in its fiscal discipline, effective organisational governance characterised by multiyear clean audits and leading the transformation agenda in medical science research. These accolades were all achieved without lowering the high standard of locally impactful and globally competitive research conducted and supported by the SAMRC. The SAMRC 2020/21 – 2024/25 Strategic Plan builds on the successes and considers, the lessons learnt, from the previous Strategic Plans and will chart a new direction – a reimagined organisation set to make further impact in the disease burden in South Africa and globally.

In the past five years, Professor Glenda Gray, the President and CEO of the SAMRC, led the implementation of our 2015/16-2019/20 strategic plan. The fast-tracking of transformation was at the top of her agenda to ensure that the medical and science graduates within the intramural programme reflect the demographic of the country. The SAMRC in this period also initiated a research capacity development programme investing in the development of PhD, post-doctoral fellows and mid-career scientists to ensure a robust pipeline of health researchers. By addressing the organisational structure and governance, the SAMRC was enabled to operate effectively and efficiently.

Transformation in science means responding to the national context, by looking at the science landscape and where interventions are needed to increase the small critical mass of African scientists. The SAMRC's Self-Initiated Research (SIR) grants, a competitive grant funding scheme, was re-engineered to address gender, racial, institutional and geographic parity. To enable health innovation, it is critical to fund and develop new human capacity in healthcare. SAMRC's research capacity development programmes are a crucial part of the transformation in science and capacitating the healthcare sector to shape a better healthcare system for all.

A publicly funded institution, the SAMRC will continue to ensure that most of the budget is allocated to research conducted and funded by the entity and less on administrative costs. This is in line with its Strategic Objective of administering the organisation effectively and efficiently. With money invested in health research, strengthening the level of research output through outputs such as publications, citations, and policy briefs is imperative. Simultaneously, enhancing research translation activities forms a key part of the SAMRC's mission. To fund the type of research that would have an impact and at a scale that the SAMRC's research can influence policy and health guidelines, multiple streams of funding are required. Now in her second tenure as President and CEO, Prof Gray in her first five years, attracted and secured additional funding through collaborations with the Bill and Melinda Gates Foundation, UK MRC-Newton Fund and collaborations with the US NIH. This strategy has increased the flow of more than R100 million into the organisation for over three years.

The SAMRC remains committed to decreasing the disease burden in South Africa through cutting edge innovations, the development of novel treatment regimens, especially vaccines, as well as improved diagnostic tools, while localising the production of new drugs and devices, to improve the health and lives of South Africans.

As the Chairperson of the SAMRC Board, I am confident that the SAMRC's 2022/23 Annual Performance Plan will support the SAMRC's agenda to lead relevant and responsive health research in South Africa and to fund research that has an impact in diseases affecting people in Africa and globally.



Professor Johnny Ndoni Mahlangu

Board Chairperson: South African Medical Research Council

Statement by the President of the SAMRC

The South African Medical Research Council (SAMRC) conducts and funds impactful health research and develops pioneers in medical innovations to improve the quality of life of people in South Africa. The country's health is a significant part of economic development: healthy populations live longer; and are more productive. There are many factors that impact population health, with South Africa facing a quadruple burden of disease: ranging from stagnating mortality in pregnant women and infants to increasing morbidity and mortality associated with non-communicable diseases such as diabetes mellitus and hypertensive heart disease, as well as the epidemics of TB and HIV, violence and injury, that overwhelm our health system.

Through research, development and technology transfer, we address South Africa's quadruple burden of disease through our intramural and extramural research units, with SAMRC intramural units prioritising research into the 10 most common causes of morbidity and mortality and associated risk factors in South Africa. The COVID-19 pandemic has also impacted on our ability to focus on these colliding epidemics.

As the country's Council conducting and funding health research, innovation and development, the SAMRC is poised to support research to decrease the disease burden in South Africa. The Strategic Plan 2020/21 – 2024/25 reinforces our research efforts across five strategic pillars: (1) The administration of health research in an effective and efficient manner; (2) The generation of new knowledge and its translation into policy and practice; (3) Supporting innovation and technology transfer to improve health; (4) Building sustainable health research capacity in South Africa; and (5) Research translation.

Driven by the five key strategic pillars, the SAMRC has pioneered cutting-edge medical innovations, the development of novel treatment regimens, vaccine development, diagnostic tools, new drugs and devices, aimed at the improvement of the health status of people in South Africa.

The Strategic Plan 2020/21 – 2024/25 serves as our guide to deliver on quality research, high impact science and to ensure that medical science flourishes. With strategic direction from the SAMRC Board, the SAMRC is set to strengthen all components of our research endeavour.

The Strategic Plan 2020/21 – 2024/25 also confirms our focus to fund research based on local development priorities, while ensuring that our research is globally relevant. Through Self- Initiated Research grants, the largest set of grant awards, where approximately 45 new three- year awards are made annually, we aim to develop scientific capacity and transformation of the pipeline of researchers. Through the Mid-Career Scientist Programme, we aim to create a new generation of science leaders.

Transformation in science remains an integral part of our strategy. To this end, we have ensured that more women and black South Africans are the beneficiaries of our masters and doctoral programmes. We have developed a cohort of interns and clinicians, including the Bongani Mayosi National Health Scholars Programme (BM-NHSP), an ambitious public-private partnership that has driven the clinician-doctoral initiative.

The Bongani Mayosi NHSP is a flagship PhD development programme and a national initiative to advance the next generation of African health and clinician scientists. The Programme is funded by the Public Health Enhancement Fund (PHEF), the PHEF is a non-profit entity to leverage and contribute to strengthening the health sector, which will lead to a stronger relationship between

public and private sectors to the benefit of all our people. The Bongani Mayosi NHSP has already produced 47 graduates (87% of which are PhDs) in various health professions. Total number of 38 women completed of which 16 are black.

Despite the tight fiscal environment, the SAMRC has delivered on impactful science and will continue to do so effectively and efficiently, as guided by the Public Finance and Management Act. As we implement the new Strategic Plan, we will ensure that our budget is spent on funding science and innovation and less on administrative costs.

Partnerships across frontiers, North-South, South-East, South-South, remain critical in furthering our mission as we rollout the Strategic Plan. Among key collaborations is the first Genomics Sequencing Facility on African soil. Part of our agreement with the Beijing Genomics Institute is to create a national asset to contribute to the better understanding of genetics and disease and enabling the SAMRC to harness the science of genomics for personalised medicine.

During the COVID-19 pandemic, we re-orientated our research funding to allocate resources to surveillance, the development of diagnostics, therapeutics, immunological research and vaccine development, demonstrating our ability to be responsive to the needs of a health response to the pandemic. Biovac, Afrigen and the SAMRC are collaborating on the establishment of the mRNA hub in South Africa in an endeavor to support vaccine development on the continent. Our recent collaboration with Dr Patrick Soon-Shiong to collaborate on a scholarship programme to advance the development of bio-manufacturing expertise in our country, will enhance our capability in vaccine discovery, evaluation and manufacturing.

Our steadfast focus on key strategic pillars guides our teams of scientists and support staff to help us in enabling the Department of Health, to deliver on their commitment and promise of a long and healthy life for all South Africans.

Professor Glenda E. Gray
President & Chief Executive Officer
South African Medical Research Council

Official Sign Off

It is hereby certified that the South African Medical Research Council Annual Performance Plan was developed by the management of the South African Medical Research Council under the guidance of Professor Johnny Mahlangu, Chairperson of the SAMRC Board and President Professor Glenda Gray.

The Annual Performance Plan takes into account all the relevant policies, legislation and other mandates for which the South African Medical Research Council is responsible.

The document accurately reflects the Impact, Outcomes and Outputs which the South African Medical Research Council will endeavour to achieve over the period 2022/2023.

Programme 1 - Administration		
Mr Nick Buick	Signature:	arm)
Chief Financial Officer Programme 2 – Core Research		
Prof Glenda Gray President and Chief Executive Officer	Signature:	
Dr Mongezi Mdhluli Chief Research Operations Officer	Signature:	
Programme 3 – Innovation and Technology		Manda of
Dr Michelle Mulder Executive Director: Grants, Innovation and Product Development	Signature:	Marian
Programme 4 – Capacity Development		
Prof Glenda Gray President and Chief Executive Officer	Signature:	
Dr Mongezi Mdhluli Chief Research Operations Officer	Signature:	

Programme 5 – Research Translation

Prof Glenda Gray President and Chief Executive Officer Dr Mongezi Mdhluli Chief Research Operations Officer	Signature:					
Mr Nick Buick Chief Financial Officer	Signature:	9 m				
Dr Mongezi Mdhluli Chief Research Operations Officer and Head Official Responsible for Planning	Signature:					
Prof Glenda Gray President and Chief Executive Officer	Signature:	Au				
Prof Johnny Mahlangu Chairperson of the Board	Signature:					
Approved:						
Dr. MJ Phaahla (MP)						

Minister of Health

PART A: SAMRC MANDATE

1 SAMRC Mandate

The mandate of the South African Medical Research Council is legislated in terms of the SAMRC Act 58, 1991 (hereafter "SAMRC Act"), which states 'the objects of the SAMRC are, through research, development and technology transfer, to promote the improvement of the health and quality of life of the population of the Republic, and to perform such functions as maybe assigned to the SAMRC by or under this Act'.

In line with this mandate, the SAMRC's Vision is to build a healthy nation through research, innovation and transformation, and the Mission is to advance the nation's health and quality of life and address inequity by conducting and funding relevant and responsive health research, capacity development, innovation and research translation.

2 Legislative and Other Policy Mandates

2.1 Constitutional mandate

The South African Constitutional base which supports the SAMRC's mandate are Chapter 2- Bill of Rights, Chapter 10 - Public Administration and Chapter 13 - Finance. The following sections of the Bill of Rights, without limitation, are particularly relevant for the SAMRC.

2.1.1 Chapter 2: Bill of Rights

Section 9: Equality

All the rights contained in this equality section

Section 10: Human Dignity

"Everyone has inherent dignity and the right to have their dignity respected and protected"

Section 12(2)(c): Freedom and Security of the person

"Everyone has the right to bodily and psychological integrity, which includes the right not to be subjected to medical or scientific experiments without their informed consent"

Section 14(a): Privacy

"Everyone has the right to privacy, which includes the right not to have the privacy of their communications infringed"

Section 16(1)(d): Freedom of Expression

"Everyone has the right to freedom of expression, which includes academic freedom and freedom of scientific research"

Section 23: Labour Relations

All the rights contained in this labour relations section

Section 24(a): Environment

"Everyone has the right to an environment that is not harmful to their health or wellbeing"

Section 27: Healthcare, food, water and social security

Everyone has a right to have access to (a) health care services, including reproductive health; (b) sufficient food and water; and social security, including if they are unable to support themselves and their dependants, appropriate social assistance

Section 28(2): Children

"A child's best interests are of paramount importance in every matter concerning the child"

Section 32: Access to Information

"Everyone has the right of access to any information held by the state"

Section 33(1): Just administrative action

"Everyone has the right to administrative action that is lawful, reasonable and procedurally fair"

Section 36(1): Limitation of rights

The rights in the Bill of Rights may be limited only in terms of law of general application to the extent that the limitation is reasonable and justifiable in an open ad democratic society based on human dignity, equality and freedom, taking into account all relevant factors....."

2.1.2 **Chapter 10: Public Administration**

Section 195: Public administration must be governed by the democratic values and principles enshrined in the Constitution, including the following principles:

- (a) A high standard of professional ethics must be promoted and maintained.
- (b) Efficient, economical and effective use of resources must be promoted.
- (c) Services must be provided impartially, fairly, equitably and without bias.
- (d) People's needs must be responded to, and the public must be encouraged to participate in policymaking.
- (e) Public administration must be accountable.
- (f) Transparency must be fostered by providing the public with timely, accessible and accurate information.
- (g) Good human-resource management and career-development practices, to maximize human potential, must be cultivated.

2.1.3 **Chapter 13: Finance**

Section 217: Procurement

- (1) When an organ of state in the national, provincial or local sphere of government, or any other institution identified in national legislation, contracts for goods or services, it must do so in accordance with a system which is fair, equitable, transparent, competitive and cost-effective.
- (2) Subsection (1) does not prevent the organs of state or institutions referred to in that subsection from implementing a procurement policy providing for
 - o categories of preference in the allocation of contracts; and
 - o the protection or advancement of persons, or categories of persons, disadvantaged by unfair discrimination.
- (3) National legislation must prescribe a framework within which the policy referred to in subsection (2) must be implemented.

2.2 Legislative mandate

2.2.1 The National Health Act, No 61 of 2003

The SAMRC is guided by this mandate to prioritize its research programmes and through the SAMRC Board interact with the NHRC and the NDoH and give effect to the mandate.

2.2.2 The SAMRC Act

The South African Medical Research Council was established in 1969 by section 2 of the South African Medical Research Council Act, No. 19 of 1969. The latter was repealed and replaced by the South African Medical Research Council Act, No. 58 of 1991. The SAMRC is a Schedule 3A Public Entity to the Public Finance Management Act, No. 1 of 1999 and reports to the National Ministry of Health.

The SAMRC is guided by South African Medical Research Council Act 1991 (Act 58 of 1991) to improve the health of the South African population, through research, development and technology transfer, for the people to enjoy a better quality of life.

Based on the mandates given by the National Health Act, No. 61 of 2003) and the SAMRC Act, SAMRC has in the past 5 years been focusing on the top ten causes of death, disability and associated risk factors. We assess how healthcare systems function to strengthen health policy, to improve the impact and efficiency of health systems and services, and provide policy makers with the tools for informed healthcare decisions.

2.2.3 Intellectual Property, Rights from Publicly Financed Research and Development Act, 2008

The SAMRC is guided by this mandate of which its aim is to provide for more effective utilization of intellectual property emanating from publicly financed research and development, to establish the National Intellectual Property Management Office and the Intellectual Property Fund, to provide for the establishment of offices of technology transfer at institutions, and to provide for matters connected therewith.

2.2.4 Other legislations, without limitation, that are applied by the SAMRC in their dayto- day activities:

- Employment Equity Act, No. 55 of 1998
- Basic Conditions of Employment Act, No. 75 of 1997
- Public Finance Management Act, No. 1 of 1999 as amended
- The Patents Act, No. 57 of 1978
- Copyright Act no. 98 of 1978 Trade Marks Act, No. 194 of 1993
- Promotion of Access to Information Act, No 2 of 2000
- Protection of Personal Information Act, No 4 of 2013
- Relevant Treasury Regulations, Instruction Notes and Guidelines

2.3 Policy Mandates

2.3.1 National Development Plan-2030

The South African Government adopted the National Development Plan 2030 (NDP-2030) in September 2012. It provides a broad strategic framework to guide key choices and actions, and common focus for actions across all sectors and sections of South African society. The plan presents a long term strategy, where in some instances policy(ies) changes may be necessary and other instances just getting basics right, holding people accountable for their actions and finding innovative solutions to complex challenges such as providing affordable access to quality health care while promoting health and wellbeing, and introduction of national health insurance with a focus on upgrading public health facilities, producing more health professionals and reducing relative cost of (private) health care. The plan has identified and adopted the following set of objectives and actions, some of which the SAMRC plays a vital role in them:

- (a) Policy making in a complex environment;
- (b) Demographic trends;
- (c) Economy and employment;
- (d) Economy infrastructure;
- (e) Environmental sustainability;
- (f) Integrated and inclusive rural economy;
- (g) Positioning South Africa in the world;

- (h) Transforming human settlements;
- (i) Improving education, training and innovation;
- (j) Promoting health;
- (k) Social protection;
- (I) Building safer communities;
- (m) Building a capable developmental state;
- (n) Fighting corruption; and
- (o) Transforming society and uniting the country.

2.3.2 National Health Insurance Policy of 2017 and National Health Insurance Bill of 2019

In 2017, the Minister of Health signed a policy document, a white paper on national health insurance. This policy lays the foundation for moving South Africa towards universal health coverage (UHC) through the implementation of National Health Insurance (NHI) and establishment of a unified health system. The move towards Universal Health Coverage (UHC) through implementation of NHI is derived from the Reconstruction and Development Programme; the Constitutional mandate based on the Section 27 of the Constitution; the 1997 White Paper for the Transformation of the Health System; Vision 2030 of the National Development Plan Vision 2030; Goal 3 of the Sustainable Development Goal and the World Health Organization frameworks on moving towards UHC with health equity and the six pillars of the WHO's health systems strengthening framework.

The aims of the National Health Insurance Bill of 2019 are to achieve universal access to quality health care services in the Republic in accordance with section 27 of the Constitution; to establish a National Health Insurance Fund (NHIF) and to set out its powers, functions and governance structures; to provide a framework for the strategic purchasing of health care services by the NHIF on behalf of users; to create mechanisms for the equitable, effective and efficient utilization of the resources of the NHIF to meet the health needs of the population; to preclude or limit undesirable, unethical and unlawful practices in relation to the NHIF and its users; and to provide for matters connected herewith.

2.3.3 **Sustainable Development Goals**

The Sustainable Development Goals (SDGs) is a plan created in 2015 after leaders of about 193 countries met and agreed to a common understanding that there is enough food to feed the world, but that was not getting shared; that there were medicines for HIV and other diseases, but they cost a lot; that earthquakes and floods were inevitable, but that the high death tolls were not; and that billions of people worldwide share their hope for a better future. The SDGs build upon the work started under the eight Millennium Development Goals, and is an ambitious plan with a set of 17 goals aiming to address poverty and hunger, and effects of climate change by the year 2030. These SDGs are set out in table 1 below:

Table 1. Sustainable Development Goals

SDG	Description
1.	No Poverty
2.	Zero Hunger
3.	Good Health and Wellbeing
4.	Quality Education
5.	Gender Equality
6.	Clean Water
7.	Affordable and Clean Energy

8.	Decent Work and Economic Growth
9.	Industry, Innovation and Infrastructure
10.	Reduced Inequalities
11.	Sustainable Cities and Communities
12.	Responsible Consumption and Production
13.	Climate Action
14.	Life Below Water
15.	Life on Land
16.	Peace, Justice and Strong Institutions
17.	Partnerships for the Goals

The work that the SAMRC undertakes respond to most of these goals as reflected in Part B of this APP.

2.3.4 Alignment to Medium-Term Strategic Framework (MTSF) 2019-2024

According to the South African President, President Matamela Cyril Ramaphosa, "the MTSF 2019-2024 is built on three foundational pillars: a strong and inclusive economy, capable South Africans and a capable developmental state". President Ramaphosa further states that "all state-owned enterprises, development finance institutions and other public entities need to align their work with the MTSF so that all the necessary public resources are harnessed and available for driving service provision. Government will work through social compacts with the private sector, labour and civil society to create an enabling environment for growth and job creation. To protect our resources, we must intensify the fight against corruption and create the foundations of a strong and inclusive economy". In line with President Ramaphosa's statement above, the SAMRC has aligned its Strategic Plan and Annual Performance Plan to six out of seven MTSF 2019-2024 priorities as in the table 2 below:

Table 2. Alignment of the SAMRC SP and APP to the MTSF

MTSF Priority	MTSF interventions	SAMRC Outcome	SAMRC Strategic Objective	SAMRC Contribution to MTSF Priority
Priority 1: A capable, ethical and developmental state	Strengthen governance system of public entities	Good governance, effective and efficient administration and compliance with government regulations	Programme 1: Administration. Output indicator 1.1.1:	Adhere to the PFMA requirements relating to compliance, governance and reporting Clean Audit
	Measures taken to eliminate wasteful, fruitless and irregular expenditure in the public sector	Good governance, effective and efficient administration and compliance with government regulations	Programme 1: Administration. Output indicator 1.1.1:	Adhere to the PFMA requirements relating to compliance, governance. Reduction/elimination of irregular, wasteful and fruitless expenditure. Clean audit
	Programme to prevent and fight corruption in government	Good governance, effective and efficient administration	Programme 1: Administration. Output indicator 1.1.1:	Adhere to the PFMA requirements relating to compliance, governance and reporting.

		and compliance with		Address reported cases of corruption.
		government regulations		
	Improve financial management capability in the public sector	Promote the organisation's administrative efficiency to maximise the funds available for research	Programme 1: Administration. Output indicator 1.2.1:	Monitor expenditure, and strengthened supply chain management and procurement system
Priority 2: Economic Transformation and Job Creation	Increased investment in gross expenditure on research and development	Promote the organisation's administrative efficiency to maximise the funds available for research	Programme 1: Administration. Output indicator 1.2.1:	80%/20% (research /administration) spend split of the government allocated SAMRC budget
		Provide funding for the conduct of health research	Program 2: Core Research Output indicators 2.3.1.	More expenditure to on research
	Expand government spend on women, youth and persons with disabilities through preferential procurement	Good governance, effective and efficient administration and compliance with government regulations	Output indicator 1.1.1: A clean audit opinion on the SAMRC from the Auditor-General	Adherence to B- BBEE Act and Treasury Regulations, Practice Notes and Circulars
Priority 3: Education, skills and Health	Implement capacity building programmes and interventions at universities	Enhancing the long-term sustainability of health research in South Africa by providing funding and supervision for the next generation of health researchers	Programme 4: Capacity Development. Output indicator 4.1.1.	Bursaries and/or scholarships and/or fellowships provided for MSc, PhD, Postdocs and Early Career Scientists
	Implement the New Generation of Academics Programme (nGAP)	Enhancing the long-term sustainability of health research in South Africa by providing funding and supervision for the next generation of health researchers	Programme 4: Capacity Development. Output indicator 4.1.1.	Bursaries and/or scholarships and/or fellowships provided for MSc, PhD, Postdocs and Early Career Scientists

Priority 4: Consolidating the social wage through reliable and quality basic services	N/A	N/A	N/A	N/A
Priority 5: Spatial integration, human settlements and local government	Profile and support enterprise development in townships through financial incentives and other non-financial forms of support	Nonspecific, but embedded in Program 1	Nonspecific, but embedded in Program 1	Adherence to B- BBEE Act and Treasury Regulations, Practice Notes and Circulars
	Training staff on diversity (gender, race and disability)	Nonspecific, but embedded in our HR practices	Nonspecific, but embedded in our HR practices	Diversity and Transformation training
Priority 6: Social cohesion and safe communities	Improve representation of the designated groups across occupational levels.	Nonspecific, but embedded in our HR practices	Nonspecific, but embedded in our HR practices	 Compliance to labour legislations Implementation of relevant HR policies and procedures Transformation practices Employment Equity reporting as required
Priority 7: A better Africa and world	Source investment (FDI) for the identified sectors in the South African economy	Support the development of new or improved innovations aimed at improving health and targeting priority health areas	Programme 3: Innovation and Technology	Leveraged funding for research and investment in technology development and innovation

2.3.5. Government to Government Collaborations

The National Department of Health (NDoH) has bilateral agreements with a number of countries forming South- South and North-South relations. This opportunity should be fully exploited by the SAMRC in the next five years.

2.3.6. South Africa - SADC and the Rest of Africa

South Africa is signatory to a number of conventions within the Southern African Development Community (SADC), African Union (AU) and WHO. Through these institutions, NDoH has certain obligations to fulfil some of them involved in health research. The SAMRC is best placed to be

government's implementing arm and following up on these on behalf of the NDoH. Closer collaboration and cooperation could for example, result in SAMRC scientists working more closely with WHO-AFRO, AU and similar structures in this region.

2.3.7 South Africa and Global Collaboration

The inclusion of South Africa into the BRIC grouping of countries comprised of Brazil, Russia, India and China in late 2010 puts an African voice at the core of the world's most dynamic economies as they consider a range of pressing global issues. The implications were that a specific health agenda was developed, and health research became a significant part of the agenda. The SAMRC, as a national research body is already collaborating with BRICS in the area of TB, HIV, Child Obesity, NCDs, Genomic research and now COVID-19. The SAMRC has developed collaborations across BRICS, Africa, Europe and the USA.

2.3.8 Communities of Funders

To fulfil its mandate and increase access to health research funding, the SAMRC has developed partnerships with local and international funders, including the NRF, NIH, EDCTP, BMGF, Newton Fund, UK-MRC, and, more recently, the Solidarity Fund, ELMA Philanthropies, Michael and Susan Dell Foundation, and others. The SAMRC is also represented on the global research funders coalition Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).

2.3.9 Other interventions

Other key interventions to improve health status include inter-sectoral collaboration with government departments responsible for key determinants of health, especially Department of Science and Innovation (DSI). Community participation and partnerships with civil society and the private sector are highly valued.

2.4 Planned policy initiatives

Policies and Governance

- (a) Knowledge, Information and Data Management Policy
- (b) Guidelines on Gene Editing
- (c) Open Access Policy
- (d) Policy on POPIA
- (e) Business Continuity Plan
- (f) Workplace Policy on COVID-19 Vaccination

2.5 Relevant Court Rulings

None

PART B: SAMRC STRATEGIC FOCUS

3 Situational Analysis

3.1 Introduction

The SAMRC receives its core funding from the National Treasury through the NDoH. SAMRC is responsible for conducting and funding relevant and responsive health research in South Africa. The SAMRC has over the past five years positioned itself to set the medical research agenda for the country, become the most significant funder of medical research in South Africa and be the custodian of all the values that embody medical research excellence. The SAMRC also receives money from the Department of Science and Innovation in the area of product development, diagnostics and vaccine development.

Through research, the SAMRC will continue to facilitate and support the NDoH in implementing evidenced-based policies and programmes. The SAMRC research programmes have in the past provided research support to the NDoH programmes through task teams, commissioned research, national surveys and ministerial committees. These have significantly contributed towards assisting the NDoH in progressively realising its set goals. Of great significance is the work undertaken by the SAMRC's Burden of Disease Research Unit that has supported the understanding of morbidity and mortality in South Africa. This work has been of relevance during the COVID-19 pandemic in quantifying excess deaths that are suggestive of a larger disease burden than suggested by confirmed COVID-19 cases.

SAMRC role and responsibilities in providing technical support to the NDoH through appropriate health research, public health and technology innovation is indispensable and contributes towards improving the health status of South Africans.

Almost three decades following the birth of its democracy, South Africa is faced with unique and major challenges that threaten the health status of its citizens. One of these challenges is the quadruple burden of disease of which South Africa is still struggling with effective strategies to control these scourges. Chief amongst the quadruple burden of diseases is the communicable epidemics of HIV and TB. South Africa has the largest HIV epidemic accompanied by one of the highest burdens of tuberculosis world-wide. Added to this is the new COVID-19 pandemic which is now contributing substantially to the local and global disease burden. In addition, South Africa is faced with the growing threat of non-communicable diseases such as obesity, diabetes and cardiovascular diseases including hypertension. Other huge threats to the nation include an epidemic of violence and injuries. Progress has been made in reducing maternal and infant mortality, but reducing neonatal mortality currently remains a challenge for the country. The growing disparity between the rich and the poor and the maldistribution of health care resources between the private and public sector poses challenges to achieving universal health coverage. In the next decade, with the implementation of the National Health Insurance, efforts to redress these inequalities will hopefully translate into quality health care for all who live in South Africa.

The SAMRC will continue to: 1) prioritise research that addresses the top 10 causes of mortality in South Africa; 2) invest in efforts to reduce morbidity and improve health outcomes; 3) fund and actively drive innovation; 4) ensure that capacity development in health research continues; and 5) renew its focus on research translation for health impact. The SAMRC will fund health research from discovery at the bench to implementation at the bedside. South Africa, with its wealth of scientists is uniquely positioned to respond on the continent to achieve solutions for the maladies that South Africans suffer from. The SAMRC will ensure, together with the scientists we fund, that the research conducted is responsive to the needs of the country. The SAMRC will continue to strengthen relationships and collaborations with universities and institution such as the National Research Foundation, Human Science Research Council, Council for Scientific and Industrial Research, Technology Innovation Agency and others.

3.2 External Environmental Analysis

3.2.1 National Health Research Committee

The NDoH established the National Health Research Committee (NHRC) in terms of section 69(1) of the National Health Act, No. 61 of 2003 (hereafter "the NHA"). The functions and powers of the NHRC, as stated in the NHA include the determination of health research to be carried out by the public health authorities, to ensure that health research agendas and research resources focus on priority health problems; to develop and advise the Minister on the application and implementation of an integrated national strategy for health research; to coordinate the research activities of public health authorities; and to identify and advise the Minister on health research priorities.

NHRC hosted a National Health Summit in 2018 with the aim of moving South Africa beyond focusing only on lessening the burden of disease as a form of improving the health status of the nation, to focusing on the broader determinants of health. This summit made the following recommendations¹:

- a) Prioritisation of the social determinants of health, including the burden of disease, for funding.
- b) Building capacity of health research human resources, along a pipeline, and in line with national transformation imperatives.
- c) Improving health research funding flows and quantification.
- d) Creating a national system of implementing health research with a national-provincial alignment of mandates, including funding.
- e) Creating an evidence-based system of health research information management through collation, monitoring, evaluation and translation of health research.
- f) Improving provision of and access to health research infrastructure, especially in academic health complexes.

Coordination and alignment of SAMRC research priority areas in the context of the NHRC is an instrumental area where the SAMRC can improve and capitalise on some of its Units' contributions and support to the NDoH. SAMRC researchers serve on strategic national, regional and international advisory committees and working groups and in doing so provide input that influences policy changes in areas affecting the health and quality of life of all living in South African. This participation culminates in the development of service delivery platforms, tools and guidelines for practice which ensure increased capacity of health workers as they benefit in training at all levels of the health system.

3.2.2 National Department of Health

The SAMRC's research mandate is guided by the SAMRC Act to conduct research that improves health systems, status, processes and health systems performance in terms of effectiveness, efficiency, equity, appropriateness and adequacy of health services. SAMRC health research aims to promote the improvement of the health and quality of life of all living in South Africa.

Over the years, the SAMRC has conducted a number of studies and surveys that provide information that were used by the Department and Government in general for planning and assessing progress towards realising Government's objectives. Some of these studies have to be conducted at regular intervals as they form part of internationally accepted surveillance systems such as the demographic and health survey. These surveys include:

- Burden of Disease (BOD),
- National Injury & Mortality Surveillance (NIMS),
- Comparative Risk Assessment (CRA),

¹ Madela-Mntla EN, Ally MM, Hawkridge A, et al. 2018 National Health Research Summit Report: Research for Health. Pretoria: Department of Health

- the Perinatal Problem Identification Programme (PPIP),
- the Child Healthcare Problem Identification Programme (Child PIP),
- the South African Community Epidemiology Network on Drug Use (SACENDU), and
- the South African Demographic Health Survey (SADHS).
- The TB Prevalence Survey
- HIV seroprevalence surveys

The South African Demographic Health Survey (SADHS) allows for comparative analysis of health systems by the World Health Organization and other multilateral agencies. Most importantly, it provides information that feeds into the National Planning Commission and similar entities. Statistics South Africa conducts the survey in partnership with the SAMRC, which provides scientific input. Inconsistent funding has resulted in South Africa not being able to conduct the SADHS with consequent inability to monitor trends in priority areas and interventions such as smoking rates, and obesity rates amongst others.

The Perinatal Problem Identification Programme (PPIP) and the Child Healthcare Problem Identification Programme are at the core of the Negotiated Service Delivery Agreement (NSDA) and relate directly to decreasing child mortality and increasing life expectancy. The district clinical specialist teams that are being deployed have to among other things contribute towards the reduction of neonatal, infant and child mortality. This intervention amongst others is a great investment for the health sector.

With the emergence of the COVID-19 pandemic, the SAMRC has led the research and innovation response, working closely with the NDoH to identify research and innovation priority areas and to provide the necessary information and tools to respond on all fronts, including surveillance, epidemiology, diagnosis, treatment and prevention.

The SAMRC's 2020/21 – 2024/25 Strategic Plan is aligned to support the NDoH and South Africa's changing health research needs. This will position the SAMRC to respond to the Sustainable Development Goals (SDGs), the National Development Plan (NDP): Vision 2030. The SAMRC aims to conduct research and implement initiatives into the following SDGs:

- (a) SDG 2, by conducting research into the nutritional needs of pregnant women, infants and children;
- (b) SDG 3 by conducting research:
 - that reduces:
 - maternal deaths and preventable deaths of new-borns and children under 5,
 - HIV. TB and other communicable diseases.
 - non-communicable diseases like hypertension, cardiovascular disease and stroke,
 - alcohol and other drug abuse,
 - violence and injury, and
 - sexual and reproductive health issues,
 - in the area of:
 - universal health coverage,
 - environmental health,
 - vaccine and affordable medicine for non-communicable and communicable diseases,
 - capacity development, and
 - climate change
- (c) SDGs 4 and 10 by addressing the SAMRCs fourth goal of developing capacity in health research:
- (d) SDG 5 by focusing on research into gender-based violence and developing interventions to address violence against women and children;
- (e) SDG 6 through collaboration with our extramural unit at the University of Fort Hare on water quality:
- (f) SDG 7,11 and 13 through ongoing research done by our intramural unit that looks at

- environmental research;
- (g) SDG 8 and 9 by focusing on Goal 3 which is to conduct research into innovation and product development; and
- (h) SDG 17 through research done by our intramural units and in collaboratoin with global research partners.

3.2.3 4th Industrial Revolution

"The Fourth Industrial Revolution (4IR) has been defined as technological developments that blur the lines between the physical, digital and biological spheres. It integrates cyber-physical systems and the Internet of Things, big data and cloud computing, robotics, artificial intelligence (AI)-based systems and additive manufacturing. Compared to previous industrial revolutions, this one is evolving at an exponential rather than a linear pace, with potentially significant impacts on work, services, education and leisure"².

SAMRC will in the next 5 years adapt its business activities to address the challenges and opportunities of the 4th Industrial revolution. One of the areas identified is digital health. According to the assembly of the World Health Organization, "the transfer of technology and knowledge on mutually agreed terms, as well as technical cooperation, aligned with Sustainable Development Goal 17 (Strengthen the means of implementation and revitalize the global partnership for sustainable development), are important in promoting digital health"3. Among other things, the assembly urged member states to (1) assess their use of digital technologies for health, including in health information systems at the national and subnational levels, in order to identify areas of improvement, and to prioritize, as appropriate, the development, evaluation, implementation, scale-up and greater utilization of digital technologies, as a means of promoting equitable, affordable and universal access to health for all, including the special needs of groups that are vulnerable in the context of digital health; (2) consider, as appropriate, how digital technologies could be integrated into existing health systems infrastructures and regulation, to reinforce national and global health priorities by optimizing existing platforms and services, for the promotion of people-centred health and disease prevention and in order to reduce the burden on health systems; and (3) to identify priority areas where normative guidance and technical assistance and advice on digital health would be beneficial, including, but not limited to, gaps in research, evidence-based standards, support to implementation and scale-up, financing and business models, content, evaluation, cost-effectiveness and sustainability, data security, ethical and legal issues, re-use and adaptation of existing digital health and other relevant tools.

3.2.4 mRNA Technology Transfer Hub

In April 2021, the WHO announced a Call for Applications for entities to host mRNA-based vaccine training and manufacture centres in Africa – as the first step to establish several regional hubs to which technologies will be transferred and subsequently passed on to neighbouring countries. This was to build on the successful influenza program where these vaccines are now manufactured in Senegal at the Pasteur Institute in Dakar.

The call was focused on private companies linking with academia and contained a significant training component for scientists from across Africa. The same WHO team involved in the Influenza program were leading the program with the support of the Medicines Patent Pool (MPP) who would conduct the due diligence and overall budget oversight. The Boston Consulting Group have been enlisted to develop the working plan.

² Department of Science and Technology 2019. White Paper on Science, Technology and Innovation - March 2019. Available at https://www.dst.gov.za/images/2019/White-paper-web_copyv1.pdf. Accessed 3 September 2019

³ The Seventy-first World Health Assembly, 26 May 2018. Available at http://apps.who.int/gb/ebwha/pdf files/WHA71/A71 R7- en.pdf. Accessed 11 July 2019

Afrigen, Biovac and the SAMRC, with the approval of the Department of Science and Innovation (DSI), submitted a proposal to the WHO for this call. It had 3 components:

Objective 1: Afrigen-Technology Transfer of an mRNA technology Platform to Afrigen and the development of GMP clinical trial batches – ideally within 12 months: This Objective is also to start a training program for Africa. It includes regulatory training as well as this will be the first mRNA SAHPRA approved facility in (South) Africa.

Objective 2: BIOVAC- Transfer of the mRNA platform from Afrigen to Biovac for scaling manufacture of vaccine candidates. mRNA manufacture is modular, so once established, it is a case of duplicating the footprint.

Objective 3: SAMRC- The national research consortium to leverage off the SAMRC's current COVID research programs (Tulio d Oliviera, Penny Moore, Patrick Arbuthnot etc) national research expertise to develop a portfolio of vaccine candidates by Africa for Africa. The lead will be the SAMRC who are also positioned to lead the clinical development.

More than 50 applications were received and included groups seeking to host the Hubs in Africa as well as pharma/biotech companies willing to tech transfer their mRNA-based platforms to Africa. The South African bid was the successful application. Afrigen, Biovac and the SAMRC were awarded the hosting of the first mRNA hub on the on 21st of June 2021 in a televised event with the DG of the WHO, Dr Tedros Adhanom Ghebreyesus, the South African and French Presidents. The WHO will be supporting the South African consortium by providing technical and regulatory support to South Africa by establishing expert panels and hiring industry experts. The first meeting between all parties was held on 19 July 2021. After the announcement, a Letter of Intent (LOI) was signed on 30 July 2021 between all parties of the hub and followed by a televised announcement by Dr Ghebreyesus and a formal Press Release.

3.2.5 COVID-19 and Cancer Vaccine Initiative

In 2021, Dr. Patrick Soon-Shiong and NANTAFRICA announced the launch of COVID-19 and Cancer vaccine initiative in South Africa in partnership with the SAMRC and Council for Scientific and Industrial Research (CSIR). The aim of this collaboration agreement is to initiate the transfer of biologic manufacturing technology for COVID-19 and cancer vaccines and next-generation cell-based immunotherapies. Professor Glenda E. Gray, President and Chief Executive Officer of SAMRC said, "The SAMRC's mission is to fund and conduct research that impacts on the lives of South Africans. SAMRC has partnered with Dr. Soon-Shiong in launching COVID-19 clinical trials in South Africa and look forward to the development of next-generation vaccines and centres of excellence for patients with infectious diseases and cancer. This collaboration will increase resources and opportunities to do just that. Cancer and Infectious Disease contribute substantially to the burden of disease in our country. Finding innovative ways to curb mortality is critical to the health of our nation".

3.3 Internal Environmental Analysis

3.3.1 Introduction

Since its inception in 1969, the Medical Research Council (SAMRC) has had many laudable achievements and has had a significant impact on public health in South Africa. A review of the organisation by an independent panel of local and international experts in 2017 (the SETI 2017 review) stated that the "SAMRC deserves praise for the revitalisation effort that has been effective in many ways and is currently still underway. The history of the organisation, and its recent focus on scientific excellence and transformation, has assured its continuation as one of South Africa's most valuable national assets and, seen as a whole, a recognised global leader in health research, defined by competence and integrity, and trusted as a partner by some of the most demanding co-funding research organisations in the world. This resurgence of value is also due to the innovative nature of the modern SAMRC (clearly shown in the success of SHIP), the scientific productivity of the extramural research units and some of the intramural research units receiving enabling funding from the Council. The prestige of the organisation is also enhanced by its leadership, and

by the directors and senior staff of the productive intramural units, which play important national (and often international) roles in the biomedical and behavioural research enterprise".

The SETI Report further reveal that the "SAMRC has undoubtedly assisted in the re-focusing of the national research effort on the three inter-related areas identified as the nation's foremost health priorities: increasing the longevity of the population, addressing maternal and child mortality and morbidity, and fighting the pandemics of HIV and tuberculosis infection. While the favourable outcomes of these campaigns are reflected in all surveillance data, some of these are due to background improvements in the social determinants of health. Even so, we are nowhere close to where South Africa should be in terms of these key priorities."

In line with health being defined as both a national economic and development goal, SAMRC has reassessed its priorities and will focus on the following areas over the next 5 years:

- 1. Knowledge Management
- 2. Research Translation
- 3. Innovation
- 4. Transformation,
- Diversity Management
- 6. Capacity Development
- 7. Open Science/Source
- 8. Data security and sharing
- 9. Balance academic and social impact of research
- 10. Environmental health,
- 11. Maternal and child health
- 12. Mental health
- 13. NHI and UHC: Focus on key areas to support roll out of NHI
- 14. Continue a search for efficacious HIV and TB vaccines
- 15. Ensure strategic investments in NCDs research
- 16. New and emerging threats such as COVID-19
- 17. Responding to emerging national health needs and global trends
- 18. Foster ethical research conduct and integrity
- 19. Explore the possibility of establishing a SAMRC Foundation
- 20. Continue to invest in infrastructure development

The Department of Science and Technology (Department of Science and Innovation from 2019) in partnership with the SAMRC established Strategic Health Innovation Partnerships (SHIP), based at the SAMRC, in 2013. SHIP funds and manages innovation projects focused on the development of new drugs, treatments, vaccines, medical devices and prevention strategies. SHIP forms part of the Grants, Innovation and Product Development (GIPD) directorate and is the key driver of innovation through the SAMRC-DSI partnership. SHIP funds projects in infectious and non-communicable diseases, preventative medicine, maternal and child health, antimicrobial resistance, digital health and medical devices. In 2021, the SHIP programme was extended by the DSI for another 2 years through a new funding contract and based on the SHIP Strategic Plan 2021-2024.

GIPD incorporates a number of additional SAMRC-specific and strategic partnership grant programmes. The former includes the Self-initiated Research grants and a selection of SAMRC-funded strategic projects, while the latter includes Grand Challenges South Africa, a number of joint funding programmes with the Newton Fund and the Healthy Life Trajectories Initiatives, a partnership with the CIHR and leading funding agencies

-

⁴ SAMRC SETI Report 2017

in China and India. In 2020, the SAMRC established a substantial COVID-19 research and innovation programme funded both from the SAMRC and the DSI and managed by GIPD and Strategic Research Initiatives. GIPD is also responsible for the management and facilitation of innovation at the SAMRC and beyond. This includes some of the above-mentioned grant programmes which fund new preventions, diagnostics, therapies and devices for priority diseases/health problems, such as HIV, TB, Malaria, and Noncommunicable diseases as well as the SAMRC Technology Transfer Office, the Global Health Innovation Accelerator, the Medical Devices and Diagnostics Innovation Cluster Programme, and the SAMRC-Jembi Collaborating Centre for Digital Health Innovation. SAMRC Offices for HIV, TB and Malaria research have been established to stimulate extramural research in these three areas.

3.3.2 Open Science

Open Science refers to an approach to research based on greater access to public research data enabled by information and communications technology tools (ICT) and platforms, broader collaboration in science – including the participation of non-scientists – and the use of alternative copyright tools for diffusing research results⁵.

SAMRC supports resolutions in the draft national declaration on open access, which states that the Universities and Science Councils resolve to:

- Work as a national collective involving government, universities, science councils and other knowledge-intensive institutions to achieve the development of open access as a default for all research produced with public funding;
- 2. Actively strengthen existing and develop new affordable open access models that bolster the quality of scholarly publishing and the research enterprise in South Africa;
- 3. Take into account the importance of high quality, peer-reviewed journals and to work constructively with other university and science systems around the world to produce new approaches to open access to these journals, in the first instance through a 'pay to publish model' rather than a 'pay to read' model:
- 4. Insist that the ownership of copyright remain with the authors and not be transferred to the publishing houses:
- 5. Strengthen existing and if necessary, develop new fully accessible national open access platforms and repositories that will provide for all information and knowledge produced through South African public funding to be freely available; and
- 6. Engage with high quality South African journal publishers to develop open access business models that will allow them to remain viable.

SAMRC joined cOAlition S, a platform created for accelerating the transition to full and immediate Open Access to scientific publications. A guiding document of cOAlition S is Plan S and aims for full and immediate Open Access to peer-reviewed scholarly publications from research funded by public and private grants. In addition to the scholarly publications, cOAlition S encourages that research data and other research outputs should be made open as possible and closed as necessary.

3.3.3 Communication

Communication is integral to the effective functioning of the SAMRC. SAMRC values open and transparent communication with all key stakeholders, including the Public, Media, Government, Universities, and Funders.

3.3.4 Research Integrity and Ethics

⁵ Department of Science and Technology 2019. White Paper on Science, Technology and Innovation - March 2019. Available at https://www.dst.gov.za/images/2019/White-paper-web-copyv1.pdf. Accessed 3 September 2019

The SAMRC researchers are required to conduct research in a professional, ethical, safe, responsible, accurate, accountable manner, and contribute to uphold the integrity, credibility and reputation/dignity of the SAMRC and its stakeholders. Respect for persons, fairness, competence, integrity, sensitivity, confidentiality and communication are values on which scientific research in the SAMRC is grounded on. The SAMRC research ethics committees will continue to review and monitor research to ensure that (1) it adheres to the, in case of humans, the broad ethical principles of beneficence and non-maleficence, distributive justice (equality) and respect for persons (dignity, and autonomy and informed consent); and (2) in cases of research involving animals, it protects their welfare and interest, and adheres to the principles of reduction, refinement and replacement.

As a way of promoting the responsible conduct of research, the SAMRC encourages all the staff members who have knowledge of occurrence of a breach of research norms and standards or research misconduct or have good reason to suspect that a breach of research norms and standards or research misconduct has occurred to promptly report any reasonable suspicions to the Research Integrity Office of the SAMRC.

SAMRC subscribes to the following principles on ethical research and scholarly publishing practices: (1) responsibility, (2) ethics and integrity, (3) methodology and data, (4) authorship, (5) acknowledgement of contributions, (6) peer review, (7) social awareness, (8) conflicts of interest, (9) editorial, (10) research publishing environment, (11) predatory journals and unethical editorial practices, and (12) quality over quantity⁶.

Through the office of the President and CEO of the SAMRC, the SAMRC Bioethics Advisory Panel (BAP) was established with the intention of enhancing ethical and human rights in all its undertakings. The BAP functions are guided by the SAMRC's values of Pioneering, Partnering, Excellence, Respect, Integrity and Citizenship. The SAMRC Bioethics Advisory Panel is established in terms of section 3.3.1 of the SAMRC Delegation of Authority Framework Policy.

The SAMRC BAP functions as an advisory panel to the SAMRC President and CEO and has no decision-making powers. Upon instruction from the SAMRC President & CEO, the SAMRC BAP will develop recommendations, statements, training, and education programs for SAMRC as well as guidelines for research and research translation based on ethics and human rights.

The SAMRC BAP comprises of members who collectively have the qualifications, expertise and experience in ethics, human rights, the law, health research and health care, and at least one member from the public. The SAMRC BAP is balanced in terms of demographic distribution. Ex-officio members are nominated from within the SAMRC.

SAMRC will, in the reporting period, embed the research integrity and ethics culture by increasing the offering of applied ethics training workshops, awareness sessions, amending and/or introducing policies and procedures on research ethics and integrity. In line with the Department of Science and Technology's White Paper on Science, Technology and Innovation 2019, SAMRC will produce "ethically acceptable, sustainable and socially desirable research and innovations outcomes which are responsive to a wide range of stakeholders and societal grand challenges, and be sensitive to the values, needs and expectations of South Africans".

3.3.5 SAMRC BOARD

The SAMRC Act No. 58 of 1991, states "the affairs of the MRC shall be managed and controlled by a Board, which shall, subject to the provisions of this Act, determine the policy and objectives of the MRC and exercise control generally over the performance of its functions, the exercise of its powers and the execution

⁶ Statement on Ethical Research and Scholarly Publishing Practices jointly issued by Academy of Science of South Africa (ASSAF), Council on Higher Education (CHE), Department of Higher Education and Training (DHET), Department of Science and Technology of South Africa (DST), National Research Foundation (NRF) and Universities South Africa (USAf). 31 July 2019

of its duties" (sections 6(1)), and "the Board shall consist of- (a) (i) a chairman; (ii) not less than 12 but not more than 14 other members who have distinguished themselves in any branch of the medical or related science; and (iii) not more than two other members, appointed by the Minister; and (b) the president, who shall serve on the Board by virtue of his office" (section 6(2).

The current SAMRC's Board term of office started on 1st November 2019 and ends on 31st October 2022. The Board is committed to ensuring that the organisation executes its mandate through its 5-year strategic plan and the related Annual Performance Plans. In the reporting period of this Annual Performance Plan, the agenda of the SAMRC will be to address the quadruple burden of diseases in terms of promoting innovative and cutting-edge science that addresses basic science, clinical research, public health research and ethics in health care research.

3.3.6 SAMRC PRESIDENT

The Board appointed Professor Glenda Gray as the first female President and CEO of the SAMRC. During her first term in office, Professor Gray led the organisation to great strengths in scientific achievements, strong organisational governance and capacity development to build the next generation of scientists in Africa, including the following:

- (a) Excellence in scientific output through an increase in National Research Foundation-rated scientists in the intra-mural units.
- (b) SAMRC partnering with HIV Vaccine Trials Network (HVTN) to conduct vaccine trials in Sub-Saharan Africa.
- (c) Funding the procurement of the national license for Cochrane Library, making South Africa the first licensed country on the continent that has allowed 60 000 people to access these publications.
- (d) Developed key collaborations leading to the first Genomics institute in Africa, Cochrane African Network and the BRICS TB Research Network.
- (e) Attended to the SAMRC's transformation agenda and invested in increasing the number of masters and doctoral students supported through SAMRC programmes.
- (f) Transformed grant funding initiatives that significantly improved funding for young scientists, black African scientists and women.
- (g) Adhered to strict corporate governance strategies in administering scientific research and received five consecutive clean audits.

As the first term of the SAMRC President and CEO, Professor Glenda Gray, came to an end in March 2019 the SAMRC Board re-appointed Professor Gray for a second term as the President and CEO of the SAMRC, effective from 1 April 2019. When announcing Professor Gray's second term in office, the then SAMRC Board Chairperson, Professor Mike Sathekge, stated that "we have no doubt that Professor Gray's leadership will expand the SAMRC's impact on science and health, her track record has proven that she is not only an outstanding scientist but a visionary whose intentions are always to advance people's lives".

3.3.7 THE EXECUTIVE MANAGEMENT COMMITTEE

The SAMRC Act No. 58 of 1991, sections 7, states "the Board shall designate an executive management committee, which shall consist of the president and so many other members, who shall be employees of the MRC, as the Board may deem necessary, and who shall, subject to the directives and control of the Board, be responsible for the management of the affairs of the MRC in accordance with the objects and policy of the MRC". The current designated members of the Executive Management Committee (EMC) are indicated in the section below. As contemplated in the Act, the composition of the EMC may change from time-to-time as deemed necessary by the Board.

3.3.8 SAMRC LEADERSHIP STRUCTURE

Below is the current high level SAMRC leadership structure, including the Board as appointed by the National Minister of Health in terms of the SAMRC Act No. 58 of 1991, section 6(2), and the Executive Management Committee as designated/appointed by the SAMRC Board in terms of the SAMRC Act No. 58 of 1991, sections 7 and 9(1).




Figure 1. High Level SAMRC Leadership

3.3.9 Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis

Table 3: SWOT Analysis

Table 3: SWOT	Allalysis
Strengths	 Solid corporate governance and strong financial management Partnership programs with different stakeholders Proven ability to raise and manage substantial funding for health R&I Professional staff and high competency (NRF ratings, Publications, Supervision, International meetings/conferences) Respect academic freedom/freedom of research Strong research outputs Capacity development Collaborations Excellent working relationship between the Board and EMC, NDoH and Portfolio Committee on Health
Weaknesses	 Research translation Diversity Management Succession planning and transformation at senior levels Lack of Biostatisticians Lack of synergy between intramural researchers Bureaucratic environment hampers progress Lack of knowledge sharing
Opportunities	 Align research with the 4IR Focus on key areas to support NHI and UHC Set new succession planning and transformation strategy Continued support to NDoH and other relevant stakeholders/partners to meet their objectives Implement strategies to grow funding Grow numbers of African and women-led Extramural Research Units Grow numbers of PhDs in the organization Implement the re-orientation of the intramural research units and platforms Collaboration with national entities to enhance health research Expand organizational move towards open access publishing
Threats	 Diminishing funding for research Research classified as low priority on the political agenda Growing trends of predatory journals Data Security Scientific misconduct Cyber security Overlap in funders of health research - delineation of mandates needed

In terms of Section 13G of the B-BBEE Act No 53 of 2003, read with regulation 12 of the B-BBEE Regulations, all spheres of government, public entities and organs of state must report on their compliance with broad-based black economic empowerment in their audited annual financial statements and annual reports

As contained in the annual report guide for Schedule 3A and 3C public entities, the SAMRC applies the relevant code of Good Practice in the manner described in the table below, and the same was included in the audited SAMRC annual report of 2020/21:

Table 4: SAMRC's B-BBEE Compliance Code of Good Practice

Criteria	Response (Yes/No)	Discussion
Determining qualification criteria for the issuing of licences, concessions or other authorisations in respect of economic activity in terms of any law?	No	Not applicable
Developing and implementing a preferential procurement policy?	Yes	SAMRC complies with the Preferential Procurement Regulations of 2017
Determining qualification criteria for the sale of state-owned enterprises?	No	Not applicable
Developing criteria for entering into partnerships with the private sector?	No	Any public private partnerships (PPP) that SAMRC may enter into will be in line with the Treasury Regulations. However, SAMRC receives some funding from the private sector, and these funds do not constitute PPP
Determining criteria for the awarding of incentives, grants and investment schemes in support of Broad Based Black Economic Empowerment?	No	However, two of the indicators of Program 4 address the issue of capacitating black/historically disadvantaged individuals

The SAMRC is committed to comply with the B-BBEE Act and transformational agenda, and has thus set aside funding to improve the organization scorecard.

4 Human Resource Management

On 31 March 2021, the SAMRC had 624 employees, with the spread according to the following race and gender profiles:




Figure 2. Employees profile by race




Figure 3. Employees profile by gender

The numbers above exclude postdocs, interns, post retirement contracts and EDCTP on the main payroll.

Table 5: SAMRC Employees

	SAMINO		-															
RACE		GENDER	March 2016– TOP MANAGEMENT	March 2021 TOP MANAGEMENT	March 2016 SENIOR MANAGEMENT	March 2021 SENIOR MANAGEMENT	March 2016 PROFESSIONALLY QUALIFIED & SPECIALISTS	March 2021 PROFESSIONALLY QUALIFIED & SPECIALISTS	March 2016 SKILLED TECHNICAL & ACADEMICALLY QUALIFIED	March 2021 SKILLED TECHNICAL & ACADEMICALLY QUALIFIED	March 2016 SEMI-SKILLED & DISCRETION DECISION MAKING	March 2021 SEMI-SKILLED & DISCRETION DECISION MAKING	March 2016 UNSKILLED ANDDEFINED DECISION MAKING	March 2021 UNSKILLED AND DEFINED DECISION MAKING	March 2016 TOTAL BY GENDER	March 2021 TOTAL BY GENDER	March 2016 TOTAL BY RACE	March 2021 TOTAL BY RACE
		Male	1	3	2	1	5	15	16	26	13	39	15	10	52	94		
African		Female	0	0	3	2	20	40	74	110	35	47	7	17	139	216	191	310
Foreign		Male	0	0	3	3	6	6	0	0	0	1	0	0	9	10	4.5	40
Nationals		Female	0	0	0	0	4	6	2	2	0	0	0	0	6	8	15	18
La d'ana		Male	0	0	4	4	8	5	9	12	1	2	0	0	22	23		00
Indian		Female	0	0	4	4	25	25	29	28	5	2	0	0	63	59	85	82
Foreign		Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Nationals		Female	0	0	0	0	1	0	1	0	0	0	0	0	2	0	1	0
Coloured		Male	0	0	4	4	7	8	19	25	7	5	5	3	42	45		140
Coloured		Female	0	0	4	6	27	26	47	45	12	8	6	10	96	95	138	140
Foreign		Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Nationals		Female	0	0	0	0	1	1	0	0	0	0	0	0	1	1	,	'
White		Male	0	1	15	11	3	3	2	3	0	2	1	0	21	20		68
VVIIILE		Female	2	2	14	11	24	27	14	6	2	2	0	0	56	48	78	00
Foreign		Male	0	0	0	1	0	0	0	0	0	0	0	0	0	1	4	5
Nationals		Female	0	0	1	2	2	2	0	0	0	0	0	0	3	4	7	J
TOTAL BY LEVEL			3	6	54	49	133	164	213	257	75	108	34	40	512	624	512	624

As of 1 February 2022, there were 7 EMC members who constituted Top Management, and were spread according to the following race and gender profiles




Figure 4. Top management profile by race




Figure 5. Top management profile by race

On 31 March 2021, senior management level, excluding the 6 EMC members who constitute Top Management, was 7.85% (49/624) of the total number of employees. The 49 members of senior management were spread according to the following race and gender profiles:




Figure 6. Senior management profile by race




Figure 7. Senior management profile by gender

Table 6: Senior Management Demographics

2016		2021		2016		2021		2016		2021		2016		2021		2016		2021		
African		African		Indian		Indian		Coloured		Coloured		White		White		Foreign National				
	5		3		8		8		8		10		29		22		4		6	
9.26%		6.12%		14.81 %		16.33%		14.81%		20.41%		53.70%		44.90%		7.41%		12.24%		
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	
2	3	1	2	4	4	4	4	4	4	4	6	15	14	11	11	3	1	4	2	
3.70%	5.56%	2.04%	4.08%	7.41%	7.41%	8.16%	8.16%	7.41%	7.41%	8.16%	12.24%	27.78%	25.92%	22.45%	22.45%	5.56%	1.85%	8.16%	4.08	

The table above excludes Top Management

The SAMRC strives towards an inclusive culture that will make all employees, managers, visitors, associates and stakeholders feel welcome, irrespective of origin, ethnicity, language, gender, religious and political conviction, social class, disability or sexual orientation.

Transformation remains an integral part of progressing towards a more inclusive and economically vibrant society. The SAMRC will continue to pursue transformation and development initiatives in order to change the demographics of the organisation, particularly at the Senior Management and Executive levels. One of the organisation's strategic goals is the transformation in science. This initiative will be achieved by supporting diversity in our new generation of a scientific cadre, particularly at the Specialist Scientist level and above.

The development of management and leadership skills will be prioritised as the SAMRC develops the pipeline of the next generation of Black Scientists. This will be achieved through the continuation of the Deputy Director programme, Accelerated Development Programmes, post-doctoral and studentships, amongst others.

The promotion of diversity is an important aspect of transformation at the SAMRC, but transformation also extends far deeper and wider than the demographics of the SAMRC community. Digital transformation has become prominent since the advent of COVID-19 pandemic. Transformation in gender equality and leadership development will continue to be an important focus area of the transformation plan. Diversity workshops and leadership training and coaching will continue during the next 5 years to change attitudes and embrace diversity in the workplace and ensure understanding of the value of diversity to create an inclusive, non-racist and gender sensitive organisational culture.

Investing in Human Capital Development and Capacity in Health Care: Bongani Mayosi National Health Scholars Programme

The NDoH and twenty-two (22) private companies, which include pharmaceutical, hospital diagnostic, corporate, healthcare supply chain, and medical scheme administration disciplines, established a vehicle called a Public Health Enhancement Fund (PHEF) to fund different programmes. The National Health Scholars Program (NHSP) is one such program funded by PHEF to leverage and contribute to strengthening the health sector that will lead to a stronger relationship between public and private sectors to the benefit of all the people of South Africa. NHSP is a partnership between the NDoH and PHEF and is a flagship PhD development program and a national asset to advance the next generation of African Health and clinical scientist. Administered by the SAMRC, NHSP has at 31 March 2021 produced 62 graduates (58 PhDs and 8 Masters) in various health professions.

In honour of one of major contributions towards health transformation, Professor Mayosi was honoured for his immense contributions and lasting legacy by renaming the NHSP "Bongani Mayosi National Health Scholars Programme".

6 SAMRC Intramural and Extramural research units, and Platforms

SAMRC intramural units are largely based at SAMRC campuses and comprise scientists directly employed by the organisation. The scope of these intramural research unit projects includes tuberculosis, HIV/AIDS, cardiovascular and non-communicable diseases, gender and health, and alcohol and other drug abuse. SAMRC extramural research units are established within research institutions (mainly universities in South Africa) with the primary goal of generating new knowledge but also to build research capacity in the discipline of health sciences. The extramural units are built on scientific excellence and leadership of an internationally recognised researcher and his/her

research team and must contribute to developing the next generation of research leaders for the country. The funding for SAMRC extramural research units represents a secure, discretionary, financial incentive which is approved in 5-year cycles up to a maximum of fifteen (15) years. Research Centres comprise scientists based at tertiary institutions who primarily conduct research on behalf of the SAMRC.

Table 7: SAMRC Health Priorities

SAMRC HEALTH PRIORITIES						
Research Programmes	Strategic Focus					
Health promotion and disease prevention	To conduct research using a life course approach to healthy lifestyles, early diagnosis, and cost-effective prevention and management of diseases through health promotion.					
Maternal, child and women's health	To improve the health status and quality of life of women and children through high-quality scientific research that informs policy and practice, improves health services, and promotes health.					
HIV, AIDS, TB, and other communicable diseases	To conduct research on preventing HIV and related co-morbidities including TB and other infectious (communicable) diseases, such as COVID-19 and malaria. In partnership with our funders and regional counterparts, this programme seeks to contribute to the national and international science system by testing TB drugs and malaria insecticides, carrying out the AIDS Vaccine project through coordinating development and testing HIV vaccines in South Africa and providing the information and tools to address the COVID-19 epidemic.					
Health systems strengthening	To contribute to health systems strengthening by undertaking systematic reviews, health policy and health systems research to provide evidence for policymakers, stakeholders and researchers seeking to address today's most pressing health challenges. The programme aims to take advantage of information and technology by exploring and expanding the role of eHealth (health informatics, digital health, tile health, telemedicine, eLearning, and mobile health) in strengthening health systems.					
Public health innovation	To promote the improvement of health and quality of life (impact prevention of ill health and improvement of public health and treatment) in the Republic of South Africa through innovation, technology development and transfer.					
Biomedical research	To conduct basic research, applied research, and transactional research to determine predisposition to disease. This understanding is important for planning effective intervention and disease control.					

Table 8: SAMRC intramural and extramural research units to the research programmes

SAMRC Research Sub- programmes	SAMRC Research Units/Platforms/Offices/Centres	Unit/Platform/ Office/Centre Director	Institution
Health promotion and disease	Alcohol, Tobacco and Other Drugs Research Unit	C Parry	Intramural Research Unit
prevention	Non-Communicable Diseases Research Unit	A Kengne	Intramural Research Unit
	Environment and Health Research Unit	A Mathee	Intramural Research Unit
	Rural Public Health and Health Transition Research Unit	S Tollman	University of Witwatersrand
	Masculinity and Health Research Unit (formerly Violence, Injury and Peace Research Unit)	A van Niekerk (Interim)	University of South Africa
	Hypertension and Cardiovascular Disease Research Unit	M Pieters	Northwest University
	Microbial Water Quality Monitoring Research Unit	A Okoh	University of Fort Hare

	Risk and Resilience in Mental	D Stein	University of Cape Town
Maternal, child and	Disorders Research Unit Gender and Health Research Unit	N Abrahams	Intramural Research Unit
women's health	Condor and rically recognish only	(Interim)	mamara ressaren em
	Maternal and Infant Health Care Strategies Research Unit	R Pattison	University of Pretoria
	Development Pathways for Health Research Unit	S Norris	University of Witwatersrand
	Child and Adolescent Lung Health Unit	H Zar	University of Cape Town
HIV, AIDS, TB and other	Centre for the Study of Antimicrobial Resistance Research Unit	K Dheda	University of Cape Town
communicable diseases	Centre for Tuberculosis Research Unit	R Warren	Intramural Research Unit
	HIV and other infectious Diseases (formerly HIV Prevention Research Unit)	A Goga	Intramural Research Unit
	HIV-TB Pathogenesis and Treatment Research Unit	S Abdool-Karim	Centre for the AIDS Programme of Research in South Africa (CAPRISA)
	Vaccine and Infectious Diseases Analytics Research Unit (formerly Respiratory and Meningeal Pathogens Research Unit)	S Madhi	University of Witwatersrand
	Precision Oncology Research Unit	Z Dlamini	University of Pretoria
	SAMRC Office of AIDS & TB Research	F Abdullah	Intramural Office
	SAMRC Office of Malaria Research	R Maharaj	Intramural Platform
	TB Platform	M van der Walt	Intramural Platform
Health	Biostatistics Research Unit	S Manda	Intramural Research Unit
systems strengthening	Burden of Disease Research Unit	R Matzopoulus and V Pillay Van Wyk (nterim)	Intramural Research Unit
	Health Services to Systems Research Unit	H Schneider	University of the Western Cape
	Health Systems Research Unit	C Mathews	Intramural Research Unit
	South African Cochrane Centre	C Wiysonge	Intramural Research Unit
	Centre for Health Economics and Decision Science - PRICELESS SA	K Hofman	University of the Witwatersrand
Public health	Drug Discovery and Development Research Unit	K Chibale	University of Cape Town
innovation	Herbal Drugs Research Unit	A Viljoen	Tshwane University of Technology
	Primate Unit and Delft Animal Center Platform	C Chauke	Intramural Platform
	The Biomedical Research and Innovation Platform	R Johson and C Pheiffer (Interim)	Intramural Platform
Biomedical	Antiviral Gene Therapy Research Unit	P Arbuthnot	University of the Witwatersrand
research	Bioinformatics Capacity Development Research Unit	A Christoffels	University of Western Cape
	Precision and Genomic Medicine Research Unit	R Ramesar	University of Cape Town
	Stem Cell Research and Therapy Research Unit	M Pepper	University of Pretoria
	Wound and Keloid Scarring Translational Research Unit	N Khumalo	University of Cape Town
	Genomics of Brain Disorders Research unit	S Seedat	Stellenbosch University
	Antibody Immunity Research Unit	L Morris	National Institute of Communicable Diseases
	Cardiometabolic Health Research Unit	T Matsha	Cape Peninsula University of Technology
	SAMRC Genomics Centre	C Kinnear	Intramural Centre

Table 9: SAMRC intramural research units' purpose

	INTRAMURAL RESEARCH UNITS					
Unit	Strategic Focus					
Alcohol, Tobacco and Other Drugs	To generate knowledge and propose policy and other interventions that will lead to a reduction in alcohol, tobacco and other drug use and the associated burden experienced by individuals and society.					
Biostatistics	To advance the health of the nation through the application, development and promotion of statistical methods in the clinical and health research conducted by the SAMRC and its stakeholders.					
Burden of Disease	To assess and monitor the country's health status and determinants of disease as well as to project the future burden of disease, in order to provide planning information to improve the health of the nation and to evaluate health information systems.					
Centre for TB Research	To run a portfolio of world class TB research ranging from basic to applied where projects are either laboratory and/or clinic based, using selected individuals or local populations as a source of data. In collaboration with national and international collaborators, areas of interest include bacteriology, immunology, genetics, bioinformatics, and clinical trials.					
Environment and Health	To conduct population-based research on environmental risks to health, with special emphasis on those living in poverty.					
Gender and Health	To improve the health status and quality of life of women through high quality scientific research on gender and health that informs the development of policy, health services and health promotion.					
Health Systems	To conduct health systems research to develop health systems, improve the organisation, efficiency, effectiveness of health systems, and increase the impact of health systems on population health and well-being. It is also to understand and evaluate how health systems function and how they can be strengthened, including how to develop and implement policies and programmes in ways that strengthen rather than undermine health systems.					
HIV Prevention	To address the challenges of the South African HIV epidemic and associated co- morbidities through a combination of biomedical, epidemiological and behavioural prevention, therapeutic and implementation science research agenda.					
Non-communicable Diseases	To formulate and apply an integrated programme of research and capacity development to improve the prevention, understanding, detection and management of NCDs, with a major focus on cardiovascular disease and metabolic disorders in South Africa.					
South African Cochrane Centre	To prepare and maintain Cochrane Reviews of the effects of healthcare interventions, and to promote access to and the use of best evidence in healthcare decision making within Africa.					

Table 10. SAMRC extramural research units' purpose

Table 10. SAMRC extramural research units purpose					
EXTRAMURAL RESEARCH UNITS					
Unit	Strategic Focus				
Antibody Immunity	To conduct research on the development of new vaccines and new approaches to controlling infectious diseases. The Unit's research seeks to establish a deeper understanding of antibody responses to infection in order to design better vaccines for the African region which bears the largest burden of infectious disease. Key focus areas are identifying antibody correlates of vaccine protection, uncovering the genetic diversity in the African antibody repertoire and isolating and engineering antibodies for passive immunity.				
Antiviral Gene Therapy	To challenge the emergence of viral infections that cause serious health problems in Sub-Saharan Africa. The long-term objectives of the unit are to advance gene therapy for treatment of viral infections, develop human capacity in the field through the training of young scientists, and to translate the unit's technologies into products.				
Bioinformatics Capacity Development	To build bioinformatics capacity in South Africa and across the African continent through research and innovation.				
Centre for the Study of Antimicrobial Resistance	To address specific aspects of bacterial multi-drug resistant pathogens, including tuberculosis. The unit's key focus areas are to better understand the pathogenesis of drug resistance by studying pharmacokinetic mismatches, conduct preliminary studies to determine the levels and efficacy of adjunct inhaled antibiotics at the disease site in TB and MDR bacterial pneumonia, and to develop and test inhaled formulations for future animal and human studies.				
Cardiometabolic Health	To provide a platform from which a team of researchers collaborate to provide an				

	EXTRAMURAL RESEARCH UNITS
Unit	Strategic Focus
	integrated research programme focusing on cardiometabolic traits (obesity, diabetes, hypertension, metabolic syndrome, and chronic kidney diseases); all with respect to inflammation, genetics, epigenetics, microbiome and oxidative mechanisms. The aim of the unit is to employ a holistic approach to investigate the context specific factors associated with diabetes and related cardiometabolic traits.
Child and Adolescent Lung Health	To focus on key health concerns affecting children and adolescents in South Africa and in Africa. The Unit's primary focus is on child lung health and the intersection of infection with emergence of chronic non-communicable diseases, addressing lung health from birth through adolescence. Studies focus on the epidemiology, aetiology and risk factors for acute and chronic lung disease and the impact of acute disease on child health and on development of chronic disease.
Centre for Health Economics and Decision Science-	To undertake rigorous and comprehensive analytical work in order to provide evidence to guide priority setting for health in South Africa. By applying innovative priority setting approaches, the Unit aims to support evidence-based resource allocation decisions in a fair and equitable way under the proposed National Health Insurance (NHI).
Developmental Pathways for Health	To investigate genetic, physiological, psychosocial and lifestyle determinants of growth and development, risk of disease, and healthy ageing across the life course.
Drug Discovery and Development	To establish a scientific infrastructure as well as capacity for drug discovery and development in the broad sense. Develop infrastructural and operational systems for new drug discovery and development. Attract young South African and African scientists thereby contributing to transformation and capacity building. Provide career development opportunities for independent academic and/or research careers.
Health Services to Systems	To focus on the mechanisms and processes through which health interventions become integrated into routine institutional environment ("real world settings") and achieve sustainable coverage and impacts at scale.
Genomics of Brain Disorders Research Unit	To identify genomic biomarkers, using a systems biology approach, for a host of brain disorders (e.g., posttraumatic stress disorder, HIV associated neurocognitive disorders, foetal alcohol spectrum disorders, schizophrenia and psychosis spectrum disorders, and Parkinson's Disease) across the lifespans.
Herbal Drugs	To conduct technologically advanced scientific research, and to make basic knowledge readily available to stakeholders, in order to promote the quality, safety and efficacy (QSE) of herbal medicines.
HIV/TB Pathogenesis and Treatment	To undertake research to reduce morbidity and mortality from HIV-TB co-infection. This Unit addresses the leading cause of death in HIV infected patients, in a setting where HIV infection is the largest single contributor to South Africa's mortality burden.
Hypertension and Cardiovascular Disease	To contribute to new clinical and epidemiological knowledge within the field of hypertension development in black populations, in order to facilitate more effective awareness, treatment and prevention programs in the future
Masculinity and Health Research Unit (formerly Violence, Injury and Peace Research Unit)	Cognisant of the gender asymmetries in health, with a historical interest in the disproportionate involvement of men in injury and violence, the SAMRC Masculinity and Health Research Unit (MaHRU) undertakes, hosts and supports evidence-based research on men, boys, masculinity and health. In addition to research, community-mobilising interventions, research-based advocacy, and public dissemination will form a strong triangulated core of the work of MaHRU
Maternal and Infant Health Care Strategies	To develop health strategies to improve the quality of care at primary and secondary care levels for mothers and infants by seeking saleable and sustainable solutions; thereby reducing maternal, perinatal and infant deaths
Microbial Water Quality Monitoring	To address the myriad of challenges in the Eastern Cape Province water sector within the overarching aim that seeks to evaluate some of the key emerging challenges in microbial water quality and safety, as a vehicle for skills and capacity development in water science especially amongst the previously disadvantages demographic groups in the Eastern Cape Province
Precision and Genomic Medicine	To use the exciting developments in the field of genomic sciences to investigate human biodiversity, and to contribute to a more proactive and preventive approach to health. Tied closely to this quest is the expansion of research to cover genome-wide investigations pertaining to the burden of disease in Southern Africa and to assess the impact of genomic variants on the health of the indigenous populations of Africa.
Vaccine and Infectious Diseases Analytics (formerly Respiratory and Meningeal Pathogens Research Unit)	To study the causes, management and prevention of pneumonia and meningitis infections with expanded initial focus on pneumococcal disease, to other common bacterial and viral causes of childhood morbidity and mortality (Group B streptococcus (GBS), rotavirus, Respiratory Syncytial Virus (RSV), pertussis, and influenza virus) as well as to integrate clinical, epidemiological and basic science research to improve the health of Africans through vaccines.
Precision Oncology Research Unit (formerly	To map the landscape of cervical and oesophageal cancer in order to understand the underlying causes of these cancers and to discover targets for the development of

EXTRAMURAL RESEARCH UNITS					
Unit	Strategic Focus				
Precision Prevention and Novel Drug Targets for HIV- Associated Cancers (PPNDTHAC))	novel and more effective targeted therapeutics. Key focus areas are to identify and comprehensively characterise the potential common and country-specific risk factors underlying high cervical and oesophageal cancer incidences and mortality rates in South Africa, Tanzania and BRICS countries.				
Risk and Resilience in Mental Disorders	To undertake research that encompasses the promotion of clinical research and the translation of basic science into clinical research, to improve diagnosis, prevention and management of mental disorders in South Africa with a focus on risk and resilience factors as they apply to key conditions in the local context, as well as the translation of clinical evidence into population-level interventions to improve mental health through primary health care and community initiatives that can be applied in diverse settings across the country and the continent, with a focus on priority illnesses given the local burden of disease.				
Rural Public Health and Health Transitions	To better understand the dynamics of health, population and social transitions in rural South Africa and southern Africa to mount a more effective public health, public sector and social response.				
Stem Cell Research and Therapy	To better understand hematopoietic stem cells (HSCs) and mesenchymal stem cells as a means to lowering the South African infection rate of both communicable and non-communicable diseases, and to use this project to initiate a gene therapy platform, from which gene therapy projects for other diseases will follow.				
Wound and Keloid Scarring (WAKS) Translational	To optimise tissue culture models for dermal wound healing after injury with particular focus to skin scarring and dermal fibrosis.				

Table 11: SAMRC Platform and specialist scientific services purpose

PLATFOR	PLATFORM and SPECIALIST SCIENTIFIC SERVICES					
Unit	Strategic Focus					
Biomedical Research and Innovation Platform (BRIP)	The Biomedical Research and Innovation Platform (BRIP) is the leading biomedical innovation platform with state-of- the-art equipment and more than 20 years of experience in the field of histology, image analysis, immunocytochemistry, molecular biology and tissue/cell culture systems. BRIP has been leading research into medical innovations for the screening, prevention and treatment of diabetes, cardiovascular disease and obesity. BRIP's capacity development programme trains the next generation of scientists in the field of Biotechnology with an emphasis on young black scientists from historically under resourced institutions.					
Primate Unit and Delft Animal Centre	PUDAC is a research support platform that provides the infrastructure to conduct pre-clinical research; scientific and technological research support; the capacity to maintain and utilise animal models (nonhuman primates, horses and rodents) and biomedical research (collaborative and contract). The platform also contributes to research by generating new in-house research to define and validate animal models; laboratory animal science and technology; providing skilled laboratory scientific and technological support.					
SAMRC Genomics Centre	The SAMRC Genomics Centre was established in 2019 in partnership with the Beijing Genomics Institute. The goal and vision for the SAMRC Genomics Centre is to grow South Africa's capacity for whole human genome sequencing and engage in an Afrocentric approach to reducing South Africa's burden of disease. The Centre conducts an in-house and collaborative genomics research program and offers whole genome, exome and transcriptome sequencing services.					
SAMRC Office of AIDS & TB Research	The Office of AIDS &TB funds and co-ordinates research in HIV/TB with the aim of optimising research funding in these areas, including the TB Report Consortium.					
SAMRC Office of Malaria Research	The Office of Malaria Research, funds and facilitates research to understand the social and biological impact of the disease as well as to develop malaria control programmes.					
TB Platform	The TB Platform oversees the execution of the National TB prevalence survey.					

7 SAMRC Research Centres

The SAMRC's Research Centres, based at universities and institutions across the country, identify and gather information on leading health concerns in South Africa like Cancer, HIV, Tuberculosis (TB) and Malaria. Each Centre is staffed with experts in the same field as the projects they direct. Many of these experts also work with external specialists on the research and funding of international projects. Over the years, the SAMRC's research has provided vital information that is used by the Department of Health and Government for health planning and assessing progress towards realising Government's objectives.

Table 12: SAMRC Research Centres

	SAMRC Research Centres						
Centre	Strategic Focus	Unit					
Cancer Centres	The explicit aim of CRCs will be to integrate cancer-related research programmes in fields such as basic laboratory and clinical sciences, prevention and control methodologies, and population-based studies, into a transdisciplinary cancer research centre that may straddle departmental and institutional boundaries	Common Epithelial Cancer Research Centre Gynaecological Cancer Research Centre					
Digital Health Centre	The SAMRC established this Collaborating Centre to incorporate the important and emerging area of digital health in the SAMRC's ambit. The centre's role is to build capacity in digital health, to coordinate digital health efforts nationally, to develop and implement a national research agenda for digital health and to develop and implement new innovations in this arena in partnership with the NDoH for improved health service	Jembi Collaborating Centre for Digital Health Innovation					

PART C – MEASURING SAI	MRC PERFORMA	NCE	

8 Institutional Programme Performance Information

8.1 **Programme 1: Administration**

Purpose: Administer health research effectively and efficiently

Table13. Programme 1 - Outcomes, Outputs, Performance Indicators and Targets

Outcome	Outputs	Output Indicator	Audited/Actual Performance		Current Year	Estimated performance	MTEF Period		
			2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
1.1. To ensure good governance, effective administration ar compliance with government regulations	Clean audit opinion	1.1.1 A clean audit opinion on the SAMRC from the Auditor-General	Clean Audit	Clean Audit	Clean Audit	Clean Audit	Clean Audit	Clean Audit	Clean Audit
1.2 To promote the organisation's administrative efficiency to maximise the fur available for research	Efficient expenditure of government allocated budget	1.2.1 Percentage of the SAMRC total budget spent on administration	16%	19%	16%	20%	20%	20%	20%

Table 14. Programme 1 - Indicators and Targets

	Reporting		Quarterly targets			
Output indicators	Frequency	Annual Target	1 st	2 nd	3 rd	4 th
1.1.1 A clean audit opinion on the SAMRC from the Auditor-General	Annually	Clean Audit				Clean Audit
1.2.1 Percentage of the SAMRC budget spent on administration	Quarterly	20%	20%	20%	20%	20%

Programme Resource Considerations

Table 15. Budget Allocation for Programme 1 (R'000)

	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
	Actual Outcome	Actual Outcome	Actual Outcome	Actual Outcome	Budget Estimates	Budget Estimates	Budget Estimates
Economic Classification of Budget							
Compensation of Employees	77 308	101 749	91 674	97 174	103 491	110 220	117 384
Goods and Services	118 178	126 715	105 623	112 101	121 390	126 898	148 651
Total	195 486	228 464	197 297	209 275	224 881	237 118	266 035

8.2 Programme 2: Core Research

Purpose: Lead the generation of new knowledge

Table 16. Programme 2 – Outcomes, Outputs, Performance Indicators and Targets

Outcome	Outputs	Output Indicator	Audited Perforr		Current Performance	Estimated Performance	MTEF Period		d
			2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
2.1. To produce and promote scientific excellence and the reputation of South African health	Published journal articles, book chapters and books	2.1.1 Number of accepted and published journal articles, book chapters and books by SAMRC affiliated and funded authors	936	1187	1261	750	700	700	600
research	Published journal articles by SAMRC grant-holders	2.1.2 Number of accepted and published journal articles by SAMRC grantholders with acknowledgement of the SAMRC	251	322	281	200	180	180	170

2.2	To provide leadership in the generation of new knowledge in health	Published journal articles with the first or last author	2.2.1. Number of accepted and published journal articles where the first and/or last author is affiliated to the SAMRC	538	672	718	450	420	300	255
2.3	To provide funding for the conduct of health research	Research grants awarded	2.3.1 Number of research grants awarded by the SAMRC	176	247	190	140	150	160	170

Table 17. Programme 2 – Indicators and Quarterly Targets

		Reporting			Quarterly targets				
Outpu	ut indicators	Frequency	Annual Target	1 st	2 nd	y targets 3 rd 170 36 101	4 th		
2.1.1	Number of accepted and published journal articles, book chapters and books by SAMRC affiliated and funded authors	Quarterly	700	140	185	170	205		
2.1.2	Number of accepted and published journal articles by SAMRC grant-holders with acknowledgement of the SAMRC	Quarterly	180	45	54	36	45		
2.2.1	Number of accepted and published journal articles where the first and/or last author is affiliated to the SAMRC	Quarterly	420	93	113	101	113		
2.3.1	Number of research grants awarded by the SAMRC	Annually	150				150		

Programme Resource Considerations

Table 18. Budget Allocation for Programme 2 (R'000)

	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
	Actual Outcome	Actual Outcome	Actual Outcome	Actual Outcome	Budget Estimates	Budget Estimates	Budget Estimates
Economic Classification of Budget							
Compensation of Employees	246 166	251 131	244 944	259 645	276 525	294 550	313 696
Goods and Services	440 955	347 069	560 263	636 587	444 570	413 473	359 983
Total	687 121	598 200	805 207	896 232	721 095	708 023	673 679

8.3 Programme 3: Innovation and Technology

Purpose: Support, through funding and other mechanisms, technology development and implementation, and innovations in health and technology delivery to improve health

Table 19. Programme 3 – Outcomes, Outputs, Performance Indicators and Targets

Outcome		Outputs		Output Indicator	Audited Perfori		Current Performance	Estimated Performance	M	TEF Perio	d
Outcome	,	Outputs		Output indicator	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
deve new impi inno aime impi heal	support the elopment of v or roved ovations ed at roving alth and jeting priority	Innovation projects and platforms funded by the SAMRC	3.1.1	Number of new innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	NEW	NEW	29	4	4	4	4
heal	Ith areas		3.1.2	Number of ongoing innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	NEW	NEW	41	30	30	30	30
or in inno aime impi heal	develop new mproved ovations ed at roving lth in key writy areas	Innovation disclosures made by SAMRC researchers	3.2.1	Number of innovation disclosures made by the SAMRC intramural research and innovation units and platforms	NEW	NEW	1	1	1	1	1

Table 20. Programme 3 – Indicators and Quarterly Targets

Outpu	t indicators	Reporting			Quarte	rly targets	
		Frequency	Annual Target	1 st	2 nd	3 rd	4 th
3.1.1	Number of new innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	Annually	4				4
3.1.2	Number of ongoing innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	Annually	30				30
3.2.1	Number of innovation disclosures made by the SAMRC intramural research and innovation units and platforms	Annually	1				1

Programme Resource Considerations

Table 21. Budget Allocation for Programme 3 (R'000)

	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
	Actual Outcome	Actual Outcome	Actual Outcome	Actual Outcome	Budget Estimates	Budget Estimates	Budget Estimates
Economic Classification of Budget							
Compensation of Employees	43 172	45 387	44 722	47 405	50 255	53 522	57 013
Goods and Services	205 172	244 909	124 854	261 728	255 937	261 554	281 974
Total	248 344	290 296	169 576	309 133	306 192	315 076	338 987

8.4 Programme 4: Capacity Development

Purpose: Build human capacity for the long-term sustainability of the South African health research

Table 22. Programme 4 – Outcomes, Outputs, Performance Indicators and Targets

		O deside l'estes	Audited	/Actual	Current	Estimated	M	TEF Perio	d
Outcome	Outputs	Output Indicator	2018/19	mance 2019/20	Performance 2020/21	Performance 2021/22	2022/23	2023/24	2024/25
4.1 To enhance the long-term sustainability of health research in South Africa by providing funding for the next	SAMRC bursaries and/or scholarships and/or fellowships provided for MSc, PhD, Postdocs and Early Career Scientists	4.1.1 Number of awards (scholarships, fellowships and grants) by the SAMRC for MSc, PhD, Postdocs and Early Career Scientists	136	157	144	130	140	150	130
generation of health researchers	Female students and/or Early Career Scientists receiving SAMRC funding	4.1.2 Number of awards by the SAMRC to female MSc, PhD, Postdocs and Early Career Scientists	New	New	106	90	100	110	108
	African South African citizens and/or permanent residents students receiving SAMRC funding	4.1.3 Number of awards by the SAMRC to Black South African citizens and permanent resident MSc, PhD, Postdocs and Early Career Scientists classified as African	New	New	86	100	105	110	90
	SAMRC scholarships/ fellowships provided for MSc, PhD, Postdocs and Early Career Scientists at HDIs	4.1.4 Number of awards by the SAMRC to MSc, PhD, Postdocs and Early Career Scientists from historically disadvantaged institutions (HDIs)	New	New	38	70	75	80	83
	MSc and PhD students graduated or completed	4.1.5 Number of MSc and PhD students graduated or completed	47	71	72	75	80	85	50

Table 23. Programme 4 - Indicators and Quarterly Targets

Output in disasters	Reporting	Annual Tannat		Quarte	rly targets	5
Output indicators	Frequency	Annual Target	1 st	2 nd	3 rd	4 th
4.1.1 Number of awards (scholarships, fellowships and grants) by the SAMF MSc, PhD, Postdocs and Early Career Scientists	RC for Annually	140				140
4.1.2 Number of awards by the SAMRC to female MSc, PhD, Postdocs and Career Scientists	Early Annually	100				100
4.1.3 Number of awards by the SAMRC to Black South African citizens and permanent resident MSc, PhD, Postdocs and Early Career Scientists classified as African	Annually	105				105
4.1.4 Number of awards by the SAMRC to MSc, PhD, Postdocs and Early Career Scientists from historically disadvantaged institutions (HDIs)	Annually	75				75
4.1.5 Number of MSc and PhD students graduated or completed	Annually	80				80

Programme Resource Considerations

Table 24. Budget Allocation for Programme 4 (R'000)

	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
	Actual Outcome	Actual Outcome	Actual Outcome	Actual Outcome	Budget Estimates	Budget Estimates	Budget Estimates
Economic Classification of Budget							
Compensation of Employees	3 399	4 480	5 050	5 353	5 706	6 077	6 475
Goods and Services	58 371	73 091	62 535	83 034	82 440	85 509	88 705
Total	61 770	77 571	67 585	88 387	88 146	91 586	95 180

8.5 **Programme 5: Research Translation**

Purpose: Translate new knowledge into policies and practices to improve health

Table 25. Programme 5 - Outcomes, Outputs, Performance Indicators and Targets

Outcome	Outputs	Output Indicator		d/Actual mance	Current Performance	Estimated Performance	N	ITEF Perio	od
			2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
5.1 To facilitate the translation of SAMRC research findings into public understanding, policy and practice	Local or international policies, reports and guidelines that reference SAMRC research	5.1.1 Number of local or international policies, reports and guidelines that reference SAMRC research	6	7	44	5	5	6	6
p , p	Reports and guidelines produced by SAMRC intramural authors	5.1.2 Number of reports and guidelines (co)produced by the SAMRC intramural researchers	NEW	NEW	58	5	5	7	9
	SAMRC researchers invited/serving on national and international bodies/committees	5.1.3 Number of national or international bodies/committees SAMRC employees serve on	NEW	NEW	90	50	50	50	50
	SAMRC supported conferences, seminars and CPD workshops	5.1.4 Number of conferences, seminars and continuing development points workshops supported by the SAMRC	NEW	NEW	26	10	10	10	10

Table 26. Programme 5 - Indicators and Quarterly Targets

Output indicators	Reporting			Quarterly targets			
	Frequency	Annual Target	1 st	2 nd	3 rd	4 th	
5.1.1 Number of local or international policies, reports and guidelines that reference SAMRC research	Bi-annually	5		2		3	
5.1.2 Number of reports and guidelines produced by the SAMRC intramural researchers	Bi-annually	5		2		3	
5.1.3 Number of national or international bodies/committees SAMRC employees serve on	Annually	50				50	
5.1.4 Number of conferences, seminars and continuing development points workshops supported by the SAMRC	Annually	10				10	

Programme Resource Considerations

Table 27. Budget Allocation for Programme 5 (R'000)

	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25
	Actual Outcome	Actual Outcome	Actual Outcome	Actual Outcome	Budget Estimates	Budget Estimates	Budget Estimates
Economic Classification of Budget							
Compensation of Employees	0	0	0	0	0	0	0
Goods and Services	0	0	0	2 174	3 246	4 332	4 343
Total	0	0	0	2 174	3 246	4 332	4 343

9 Planned performance over the five-year planning period

9.1 Implementation Plan for Biostatistics Capacity Development in Collaboration with Hasselt University

Five South African Masters students were selected to enrol for the UHasselt Master in Statistics program via training combination with distance learning. The duration of the program is two years. The criteria for selection of students and the minimum requirements for entry into the program was jointly decided on with UHasselt and the SAMRC. In view of the performance of South African students previously enrolled in the distance learning program, we have identified that local support in terms of additional in-person lectures and tutorial sessions, may increase the chances of students successfully completing the modules. We therefore propose the following:

- a) Statistics Faculty from within South Africa and its affiliated institutes, with specific expertise in each course module, will be selected by Hasselt University, to deliver additional training for the students in the first year of the program. Our previous experience has shown that full distance learning has proven ineffective. To ensure that the South African faculty are well acquainted with the course material and the examination procedure, we propose short-term training at Hasselt University.
- b) The examinations for the first year of the program will take place at a central examination venue in South Africa.
- c) The research project, to be taken in the second year, will be undertaken with a Co- supervisor from South Africa. This project will focus on real data analysis and methodological area that is highly relevant in the South African or Sub-Saharan African context.

9.2 **Doctoral scholarships**

Between 5-10 South Africans will be awarded scholarships to embark on their studies at Hasselt University. There are two possible alternatives: 1) Sandwich or Joint PhDs with a local co-promoter and main promoter at Hasselt University: The scholarship will include a daily allowance and operational funds for a maximum period of twelve months in total (split over four years) in Hasselt University, Belgium. 2) Full time study at Hasselt University: The scholarship will cover living expenses, operational costs and tuition fees for a maximum period of four years in Belgium.

9.3 Extramural Research Units

The SAMRC has grown the diversity of the extramural research units (EMU). In the next five years, the SAMRC to increase numbers of EMUs, particularly black and female led EMUs.

9.4 Collaborating Centres for Cancer

Two collaborating centres for cancer have been funded for 3 years. Progress has been made and the 5-year strategic plan should take into account the value of further investment. Discussions with CANSSA should be considered to leverage limited funds.

9.5 TB/HIV Collaborating Centres

These collaborating centres have been very productive and have formed the basis of the TB report programme and demonstrate the value to a clinical network around diseases. The centres have now been grouped into a TB Report Consortium.

9.6 Collaborating Centre for Digital Health Innovation

The digital health innovation collaborating centre completed its first for 3-year term in 2020. An assessment of the outputs and impact of the centre should be conducted and utilized to determine

the merits of additional investment for a second term.

9.7 Request for Application (RFAs) for research priorities identified through the strategic planning process and National Priorities.

The SAMRC will continue to expand its portfolio of funded projects (both research and innovation grants) through the Request for Applications process, which allows for open competition for SAMRC grants. RFAs are designed based on identified research priorities and the availability of funding; and are often linked to partnership agreements signed with strategic funding partners. The RFA for Self-initiated Research grants is run annually for 3-year investigator-initiated projects in research priority areas that are determined annually. RFAs are also utilized, as necessary to identify additional extramural research units. The RFA process includes independent peer review and decision making based on scientific merit and other important imperatives such as transformation and equitable distribution of funding by priority area and institution.

9.8 Driving Transformation and Capacity Development.

Both in intramural domain and extramural domain drive processes for achieving this with strategic partners like National Research Foundation (NRF), Public Health Enhancement Fund (PHEF), Department of Higher Education (DHE).

9.9 Funding and Budget Related Issue in key areas of savings and reprioritisation

Support and Administration processes are consistently being reviewed to improve their efficiency and cost effectiveness. Annual operational increases for Support and Administration are also below inflation to ensure maximum funding is allocated to the core business, research. The main aim is to ensure that the SAMRC has divisions that can adequately render professional, cost effective, administrative support to the core business (research) of the SAMRC.

Key areas of reprioritisation over the MTEF include R10m per annum over the MTEF to assist with COVID-19 mRNA vaccine development as well as other COVID-19 research of R13m in 2022/23, R13m in 2023/24 and R19m in 2024/25.

Funds amount to R13.5m per annum over the MTEF have been earmarked to fund projects to generate leverage funding of at least the equivalent amount from collaboration partners and funders.

In early 2013, the SAMRC and National Institutes of Health, USA (NIH) entered into a Memorandum of Understanding (MOU) with the intent to:

- Establish or expand long-term relations between scientists from South Africa and the United States, in order to perform high-quality biomedical and behavioural health research;
- Build long-term collaborations in biomedical and behavioural health science between the NIH Institutes and South African universities and other institutions; and
- Explore and support consultation, collaboration and research projects and activities in specific fields of mutual interest.

This SAMRC-NIH collaboration continues and the SAMRC's contribution to this joint initiative over the MTEF period is as follows:

2022/2023: R45m 2023/2024: R45m

10 Programme Resource Considerations

Table 28. Resource consideration

Statement of financial perfomance	Budget	Audited outcome	Budget	Audited outcome	Budget	Audited outcome	Budget estimate	Approved budget	Outcome/ Budget Average %	Average growth rate (%)	Expen- diture/ total: Average (%)	Mediu	ım-term es	timate	Average growth rate (%)	Expen- diture/ total: Average (%)
R thousand	2018	3/19	201	9/20	202	0/21	202	21/22	201	8/19-2021/2	22	2022/23	2023/24	2024/25	2021/22 -	- 2024/25
Revenue																
Non-tax revenue	418 386	564 706	423 680	550 907	499 465	464 270	529 963	530 963	112,8%	-2,0%	41,4%	545 049	527 184	536 857	0,4%	39,6%
Sale of goods and services other than capital assets	387 436	517 258	395 812	500 598	476 057	431 767	483 708	484 749	111,0%	-2,1%	37,9%	499 669	483 784	493 542	0,6%	36,3%
Other non-tax revenue	30 950	47 448	27 868	50 309	23 408	32 503	46 255	46 214	137,4%	-0,9%	3,5%	45 380	43 400	43 315	-2,1%	3,3%
Transfers received	624 829	624 829	687 247	686 666	705 285	854 613	851 714	851 714	105,2%	10,9%	58,6%	779 523	797 597	833 417	-0,7%	60,4%
Total revenue	1 043 215	1 189 535	1 110 927	1 237 573	1 204 750	1 318 883	1 381 677	1 382 677	108,2%	5,1%	100,0%	1 324 572	1 324 781	1 370 274	-0,3%	100,0%
Expenses															-	
Current expenses	1 070 580	1 111 222	1 042 330	1 104 966	1 149 108	1 128 190	1 273 973	1 396 277	104,5%	7,9%	92,4%	1 241 833	1 251 974	1 269 279	-3,1%	92,4%
Compensation of employees	361 957	370 045	396 022	402 747	409 795	386 390	442 595	409 577	97,4%	3,4%	30,8%	435 977	464 369	494 568	6,5%	32,4%
Goods and services	687 123	726 273	623 577	685 166	716 022	715 094	807 378	962 700	109,0%	9,8%	60,0%	781 406	760 710	744 961	-8,2%	58,1%
Depreciation	21 500	14 591	22 731	16 855	23 291	26 583	24 000	24 000	89,6%	18,0%	1,6%	24 450	26 895	29 750	7,4%	1,9%
Interest, dividends and rent on land	-	313	-	198	-	123	-	-	-	-100,0%	0,0%	-	-	-	-	-
Transfers and subsidies	76 733	81 499	90 426	89 565	91 993	111 475	111 009	108 924	105,8%	10,2%	7,6%	101 727	104 161	108 945	0,0%	7,6%
Total expenses	1 147 313	1 192 721	1 132 756	1 194 531	1 241 101	1 239 665	1 384 982	1 505 201	104,6%	8,1%	100,0%	1 343 560	1 356 135	1 378 224	-2,9%	100,0%
Surplus/(Deficit)	(104 098)	(3 186)	(21 829)	43 042	(36 351)	79 218	(3 305)	(122 524)		237,5%		(18 988)	(31 354)	(7 950)	-59,8%	

The SAMRC has four major funding sources and 2 types of funding: (a) baseline funding from National Treasury through NDoH to fund the core business of the SAMRC in line with section 3, object of the MRC, of the SAMRC Act No 58 of 1991. (b) funding from DSI for health innovation and technology development, in terms of Programme 3 of our SP and APP. (c) Internal (NDoH and DSI) additional funding and externally leveraged (national and international funders to funding) to supplement funding needed to address research priorities. (d) external contract funding that SAMRC researchers secure from national and international funders for specific projects in line with the SAMRC mandate.

11 Key Risks which may affect achievement of the outcomes

Table 29. Key risks on outcomes

Key outcome	Key risk context	Key mitigation measures
Programme 1: Administer	health research effectively and effici	ently
governance, effective administration and compliance with government regulations	Potential non-compliance to legal and regulatory requirements as well as policies and procedures	 Policies, guidelines and SOPs Legal & Compliance Services Occupational Health and Safety support
	Regulators and regulations pertaining to clinical research	 Human and animal ethics committees Research Integrity Office Research Ethics Policy Responsible Conduct of Research Guidelines
	Sustainability of the Defined Benefit (DB) fund	 Freeze on increase in DB pensionable salary in excess of annual increase Statutory actuarial valuation
	Lack of a broader SAMRC business continuity programme	 Environmental monitoring devices Business Continuity Plan Back-up generators and UPS IT Disaster Recovery Policy and Plan Daily back-ups

Key outcome	Key risk context	Key mitigation measures
To promote the organisation's administrative efficiency to maximise the funds available for research	Inefficiencies within HSE and various corporate processes, including contract & grant management, procure to pay, human resource management	 HSE Office Management oversight Online helpdesk services and technology Contracts for major procurement spends Ongoing engagement with stakeholders Policies, processes, SOPs Career Progression and Advancement process Roll out of leadership interventions, coaching and mentoring programmes Organizational performance monitoring
	Insufficient infrastructure management and revitalisation of Delft site	 Asset management and verification Capital project refurbishment Preventative maintenance plans Defined strategies for the upgrading of the Delft facilities Revamping office space in Ridge Road building
	Loss / theft of data	 Layer 7 firewall implemented Segmented networks Monitoring of internet traffic Periodic penetration tests
	Implementation of agreed strategic actions	Formalised tracking on agreed actions and report back process
	Organisational practices around environmental sustainability	Various strategies implemented and continually enhanced to reduce SAMRC's carbon footprint.
Programme 2: Lead the ger	neration of new knowledge	
To produce and promote scientific excellence and the reputation of South African health research	Poor research governance	 Established research integrity office Research policies, guidelines and SOPs Human and animal ethics committees established
	Formation of NAPHISA	· On-going engage with DoH and NAPHISA
	COVID 19 pandemic	Various strategies implemented and continually enhanced to mitigate the impact of the pandemic on SAMRC's staff and objectives
	Maintaining research integrity	 External and internal quality review process Scientific advisory committees Research Integrity Office Quality review process for externally funded projects
To provide leadership in the generation of new knowledge in health	Transformation and diversity challenges	EE Strategy and Plan Appointment of Intra-Mural Unit Deputy Directors Diversity intervention initiatives / programs Succession planning

Key outcome	Key risk context	Key mitigation measures
	Sustained leadership at EMC level	Development of define strategies and continually enhanced to strengthened sustained leadership
	Research platforms / centre and Non-human primate research	Development of revised / enhanced strategic plans
	Maintain a fit for purpose intra- mural program	Internal 5-year strategic reviews Increased capacity development funding
	Implementation of the National Health Insurance (NHI)	SAMRC response to RFAs Intramural programs support NHI research
	Cannabis Research	SAMRC represented at the inter-ministerial committee on Cannabis
To provide funding for the conduct of health research	Changes in long term future focus of research funding required	 In discussion on the future refocus of research funding Ongoing engagement with stakeholders New strategic plan for 2021 - 2025
	Inability to sustainably grow funding	Dedicated on-going investigation for further international funding opportunities
	Relationship with NDoH and NT	Representation on Committees Ongoing engagement with stakeholders
Programme 3: Support three	Social Impact Bonds (SIBs)	Assigned team dedicated to identifying and implementation a SIB project(s) * Preliminary funding approved to investigate opportunities technology development and implementation,
	~ · · · · · · · · · · · · · · · · · · ·	health and technology delivery to improve health
To support the development of new or improved innovations aimed at improving health and targeting priority health research areas of focus	Lack of further development and commercialization of (a) SAMRC-owned and (b) SAMRC-funded innovations	 IP Policy and strategy Commercialisation plan External partnerships assistance with commercialization and progressing innovations to market
	capacity for the long-term sustainab	ility of the South African health research
To enhance the long- term sustainability of health research in South Africa by providing funding for the next generation of health researchers	Limited research capacity	 Capacity building strategy for supporting the development of HDI research scientist Scholarship and bursary programs Strategic relations with institutions for collaboration and accessing researchers to build clinical research capacity
	Funding scientific excellence	 Independent international reviews Scientific advisory committee established Quality review process for all externally funded projects
Programme 5: Translate ne	w knowledge into policies and praction	ces to improve health
of SAMRC research findings into public understanding, policy and practice strengthened policy and practice		 Spending model with long term return defined Dedicated on-going investigation for further international funding opportunities Workshops on research translation

12 Public Entity Description:

Table 30. Entity description

Name of the Public Entity	Mandate	Outcomes	Current Annual Budget (R thousand)
South African Medical Research Council	To improve the health of the country's population, through research, development and technology transfer	Refer to sections 7.1 to 7.5 of the strategic plan	R597 101 (excl. VAT)

13 Infra-structure Projects

Table 31. Infrastructure projects

No.	Project name and description	Programme	Output	Project start date	Project completion date	Total Estimated cost	Current year Expenditure
1	Replace air- conditioning in all regions	Programme 1	Upgrading of air-conditioning	Apr-22	Mar-23	1 000 000.00	0.00
2	Internal renovations & Construction - CPT Building D	Programme 1	Well maintained buildings	Apr-22	Mar-23	15 000 000.00	0.00
3	Furniture-for Renovated Areas	Programme 1	Well maintained buildings	Apr-22	Mar-23	1 000 000.00	0.00
4	Minor Building Works	Programme 1	Well maintained buildings	Apr-22	Mar-23	1 000 000.00	0.00
5	Internal renovations & Construction - CPT Delft Building D. Stage 1	Programme 1	Well maintained buildings	Apr-22	Mar-23	7 700 000.00	0.00
6	Internal Renovations - Ridge Road 4th and 5th floors	Programme 1	Well maintained buildings	Apr-22	Mar-23	10 000 000.00	0.00
7	Internal renovations & Construction - CPT NIVS Building	Programme 1	Well maintained buildings	Apr-22	Mar-23	10 000 000.00	0.00
8	Pretoria - Fourth Floor Internal Renovation	Programme 1	Well maintained buildings	Apr-22	Mar-23	10 000 000.00	0.00

14 Public Private Partnerships

None

PART D – TECHNICAL INDICATOR	DESCRIPTIONS	
		50 L D o g o

Table 32. Programme 1 - Administration

Indicator Title	1.1.1 A clean audit opinion on the SAMRC from the Auditor- General
Definition	Audit opinion expressed by auditor general
Source of Data	Documented Evidence: Annual Report; Auditor General's
	Report
Method of Calculation/Assessment	No calculation required
Means of Verification	Final audit report determines the validity of the performance
Assumptions	All records and evidence presented to the Auditors are reliable
	and valid
Calculation Type	Non-cumulative
Reporting Cycle	Annual
Desired Performance	To achieve a clean audit opinion from the Auditor General
Indicator Responsibility	CFO

Indicator Title	1.2.1 Percentage of the SAMRC budget spent on			
	administration			
Definition	Percentage of the SAMRC total budget spent on salaries and			
	operations of all corporate administrative functions			
Source of Data	Documented Evidence: Financial Records			
Method of Calculation/Assessment	Count			
Means of Verification	Management reports received from Finance			
Assumptions	The financial records at the SAMRC are reliable and valid			
Calculation Type	Non-cumulative			
Reporting Cycle	Quarterly			
Desired Performance	To achieve set targets for the reporting period			
Indicator Responsibility	CFO			

Table 33. Programme 2 - Core Research

14510 0011 10g14111110 Z				
Indicator Title	2.1.1 Number of accepted and published journal articles, book			
	chapters and books by SAMRC affiliated and funded			
	authors			
Definition	Total number of accredited publications in which one of the			
	authors has a listed affiliation as the SAMRC, usually because			
	the author is an SAMRC intra- or extramural unit, funded			
	through baseline or contract funds. Publications are full length			
	papers, short communications, letters, editorials and			
	commentaries. Publications are regarded as accredited when			
	they are published in journals.			
Source of Data	Knowledge & Information Management (KIMS)			
Method of Calculation/Assessment	Count the number of published journal articles, book chapters			
	and books with an author declaring employment by, affiliation			
	to an entity of, or funding support from SAMRC.			

Means of Verification	 Submissions received by the due date will be included in the relevant quarter. The earliest publication date on the publication is the date used for allocation of publication to a specific quarter of the financial year. Each publication can only be counted once. In cases where the article is published electronically, e.g. e-pub; published ahead of print, and there is a print version of the same article to follow, the earliest date of publication will be considered for counting. In cases where the researcher is both the author/editor of the book but also published a chapter in a book, it can be counted either as a chapter or a book, and not both.
Assumptions	The evidence presented to the auditors is reliable, relevant
	and valid
Calculation Type	Cumulative
Reporting Cycle	Quarterly
Desired Performance	To achieve set targets for the reporting period
Indicator Responsibility	President & CEO and CROO

Indicator Title	2.1.2 Number of accepted and published journal articles by
	SAMRC grant-holders with acknowledgement of the
	SAMRC
Definition	Total number of accredited publications that mention SAMRC
	funding. Publications are full length papers, short
	communications, letters, editorials and commentaries.
	Publications are regarded as accredited when they are
	published in journals. These publications must mention the
	SAMRC by name in the acknowledgement section of the
	journal article. The authors may or may not be affiliated with the
	SAMRC
Source of Data	Knowledge & Information Management (KIMS)
Method of Calculation/Assessment	Count the number of published journal articles by SAMRC
	grant-holders during the reporting period, with an
	acknowledgement of SAMRC
Means of Verification	Submissions received by the due date will be included in
	the relevant quarter.
	The earliest publication date on the publication is
	the date used for allocation of publication to a specific quarter of the financial year.
	Each publication can only be counted once.
	In cases where the article is published electronically,
	e.g. e-pub; published ahead of print, and there is a print
	version of the same article to follow, the earliest date of
	publication will be considered for counting.
	 In cases where the researcher is both the author/editor of
	the book but also published a chapter in a book, it can be
Annual Control	counted either as a chapter or a book, and not both.
Assumptions	The evidence presented to the auditors is reliable, relevant and
	valid
Calculation Type	Cumulative
Reporting Cycle	Quarterly
Desired Performance	To achieve set targets for the reporting period
Indicator Responsibility	President & CEO and CROO

Indicator Title	2.2.1 Number of accepted and published journal articles where the first and/or last author is affiliated to the SAMRC
Definition	Total number of publications (original articles, editorials, commentaries or letters) where the first and/or last author has a listed affiliation as the SAMRC, usually because the author is in an SAMRC intra or extramural research unit, funded through baseline or contract funds.
Source of Data	Knowledge & Information Management (KIMS)
Method of Calculation/Assessment	Count the number of published journal articles with the first or last author declaring employment by, affiliation to an entity of, or funding support from SAMRC.
Means of Verification	 Submissions received by the due date will be included in the relevant quarter. The earliest publication date on the publication is the date used for allocation of publication to a specific quarter of the financial year. Each publication can only be counted once. In cases where the article is published electronically, e.g. e-pub; published ahead of print, and there is a print version of the same article to follow, the earliest date of publication will be considered for counting. In cases where the researcher is both the author/editor of the book but also published a chapter in a book, it can be counted either as a chapter or a book, and not both.
Assumptions	The evidence presented to the auditors is reliable, relevant and valid
Calculation Type	Cumulative
Reporting Cycle	Quarterly
Desired Performance	To achieve set targets for the reporting period
Indicator Responsibility	President & CEO and CROO

Indicator Title	2.3.1 Number of research grants awarded by the SAMRC
Definition	Total number of Research grants awarded to academic
	institutions by the SAMRC
Source of Data	Departmental records
Method of Calculation/Assessment	Count the number of research grants awarded by the SAMRC
Means of Verification	EMC submission and approval; Letter/signed contract of renewal/new award and spreadsheet from SIR, GIPD, Office for AIDS, TB and Malaria Research, SAAVI and Flagship. Team validate the source documents to check whether the new/renewal research grant falls within the reporting period
Assumptions	The evidence presented to the auditors is reliable, relevant
	and valid
Calculation Type	Cumulative
Reporting Cycle	Annual
Desired Performance	To achieve set target for the reporting period
Indicator Responsibility	Director: GIPD

Table 34. Programme 3 - Innovation and Technology

Indicator Responsibility

nav projecte
ogy projects ping, testing
alth solutions
IRC that are
ting new or
ited to, new
ons, medical
ew/additional
projects (i.e.
ion projects
the above
ew and/or
the above
es within the
es willin the
ogy projects
ogy projects ping, testing
•
oing, testing oilth solutions
oing, testing alth solutions
oing, testing alth solutions RC that are ting new or
oing, testing alth solutions RC that are ting new or ss within the
oing, testing alth solutions RC that are ting new or ss within the received a
oing, testing alth solutions RC that are ting new or ss within the
oing, testing alth solutions RC that are ting new or ss within the received a d and those
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding lose.
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding lose.
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding lose.
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding lose.
coing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding cose. The SAMRC ting new or
oing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding lose.
coing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding cose. The SAMRC ting new or
coing, testing alth solutions RC that are ting new or ss within the received a d and those during the sing funding cose. The SAMRC ting new or
1 ti i o e r

Exec Director: GIPD

Indicator Title	3.2.1 Number of innovation disclosures made by the SAMRC intramural research and innovation units and platforms
Definition	New disclosures made to the SAMRC Technology Transfer Office of possible new intellectual property with potential for social and/or economic impact
Source of Data	Departmental records
Method of Calculation/Assessment	Count the number of invention disclosure forms submitted to the SAMRC TTO
Means of Verification	New invention disclosure forms
Assumptions	Evidence presented to AGSA is valid and reliable
Calculation Type	Cumulative
Reporting Cycle	Annual
Desired Performance	To achieve set targets for the reporting period
Indicator Responsibility	Exec Director: GIPD

Table 35. Programme 4 - Capacity Development

La Parata Title	4.4.4. November of accords (askalansking fallocation and
Indicator Title	4.1.1 Number of awards (scholarships, fellowships and
	grants) by the SAMRC for MSc, PhD, Postdocs and
	Early Career Scientists
Definition	Total number of total or part scholarships/ fellowships and
	grants funded by the SAMRC for post-graduate study at
	masters, doctoral and post-doctoral levels
Source of Data	RCD records
Method of Calculation/Assessment	Count of the number of scholarships/fellowships/grants
	funded by the SAMRC to enhance sustainability of health
	research in South Africa
Means of Verification	EMC submission and approval (sign off) to indicate the
	number of scholars funded
	signed contracts and proof of payment
	list of declined awards to verify that those scholars
	were not included in the list submitted to SPMO
Assumptions	The evidence presented to the auditors is reliable, relevant
	and valid
Calculation Type	Cumulative
Reporting Cycle	Annual
Desired Performance	To achieve set target for the reporting period
Indicator Responsibility	President & CEO and CROO

Indicator Title	4.1.2 Number of awards by the SAMRC to female MSc,
	PhD, Postdocs and Early Career Scientists
Definition	Total number of total or part awards by the SAMRC to female
	recipients for post-graduate study at masters, and doctoral
	levels
Source of Data	RCD records
Method of Calculation/Assessment	Count of the number of grants/scholarships/fellowships
	awarded to female recipients by the SAMRC
Means of Verification	EMC submission and approval (sign off) to indicate the number of female scholars funded
	signed contracts and proof of payment
	 list of declined awards to verify that those scholars
	were not included in the list submitted to SPMO

Assumptions	The evidence presented to the auditors is reliable, relevant a	
	valid	
Calculation Type	Cumulative	
Reporting Cycle	Annual	
Desired Performance	To achieve set target for the reporting period	
Indicator Responsibility	President & CEO and CROO	
Indicator Title	4.1.3 Number of awards by the SAMRC to Black South Africar	
	citizens and permanent resident MSc, PhD, Postdocs and Early Career Scientists classified as African	
Definition	Awards by the SAMRC to Black South African citizens and permanent resident MSc, PhD, Postdocs and Early Career Scientists classified as African	
Source of Data	RCD records	
Method of Calculation/Assessment	Count of the number of awards to African South African citizens and permanent resident students receiving SAMRC funding	
Means of Verification	 EMC submission and approval (sign off) to indicate the number of scholars funded signed contracts and proof of payment list of declined awards to verify that those scholars were not included in the list submitted to SPMO 	
Assumptions	The evidence presented to the auditors is reliable, relevan and valid	
Calculation Type	Cumulative	
Reporting Cycle	Annual	
Desired Performance	To achieve set target for the reporting period	
Indicator Responsibility	President & CEO and CROO	
Indicator Title	4.1.4 Number of awards by the SAMRC to MSc, PhD Postdocs and Early Career Scientists from historically disadvantaged institutions (HDIs)	
Definition	Total number of scholarships/fellowships for students of SAMRC grant holders from previously disadvantaged institutions (HDIs)	
Source of Data	RCD records	
Method of Calculation/Assessment	Count of the number of scholarships/fellowships for students or SAMRC grant holders from previously disadvantaged institutions (HDIs)	
Means of Verification	 EMC submission and approval (sign off) to indicate the number of scholars funded signed contracts and proof of payment list of declined awards to verify that those scholars were no included in the list submitted to SPMO 	
Assumptions	The evidence presented to the auditors is reliable, relevant and	

Indicator Title	4.1.5	Number	of	MSc	and	PhD	students	graduated	or
		complete	ed						

President & CEO and CROO

To achieve set target for the reporting period

valid

Annual

Cumulative

Calculation Type

Reporting Cycle
Desired Performance

Indicator Responsibility

Definition	Develop human capital within the organisation to ensure excellence in all areas of operation
Source of Data	RCD records
Method of Calculation/Assessment	Count the number of MSc and PhD students graduated or completed
Means of Verification	Documentary evidence received from the relevant academic institution or copy of certificate from graduate
Assumptions	The evidence presented to the auditors is reliable, relevant and valid
Calculation Type	Cumulative
Reporting Cycle	Annual
Desired Performance	To achieve set target for the reporting period
Indicator Responsibility	President & CEO and CROO

Table 36. Programme 5 - Research Translation

Indicator Title	5.1.1 Number of local or international policies, reports and guidelines that reference SAMRC research
Definition	Total number of local/international policies, reports and
	guidelines that have been influenced by SAMRC research
Source of Data	Unit records
Method of Calculation/Assessment	Count the number of local/international policies and guidelines
	that reference SAMRC research
Means of Verification	 Units are required to have their updated publication lists and documentary evidence (publication / journal) uploaded to the SAMRC Homepage. All outputs must be verifiable for audit purposes. This indicator has external interdependencies hence the SPMO team having to physically search for the publications where the SAMRC is referenced.
Assumptions	The evidence presented to the auditors is reliable, relevant and valid
Calculation Type	Cumulative
Reporting Cycle	Bi-annual
Desired Performance	To achieve set targets for the reporting period
Indicator Responsibility	President & CEO and CROO

Indicator Title	5.1.2 Number of reports and guidelines (co)produced by the		
	SAMRC intramural researchers		
Definition	Total number of reports and guidelines produced by SAMRC		
	intramural researchers		
Source of Data	Unit records/Internet search		
Method of Calculation/Assessment	Count the number of reports and guidelines produced by		
	authors within the SAMRC intramural research units		
Means of Verification	 Publications sourced by the due date will be included in the relevant quarter. The earliest publication date on the publication is the date used for allocation of publication to a specific quarter of 		
	the financial year.		
Assumptions	The evidence presented to the auditors is reliable, relevant		
	and valid		
Calculation Type	Cumulative		
Reporting Cycle	Bi-annual		
Desired Performance	To achieve set targets for the reporting period		
Indicator Responsibility	President & CEO and CROO		

Indicator Title	5.1.3 Number of national or international bodies/ committees		
	SAMRC employees serve on		
Definition	Total number of SAMRC intramural researchers who have		
	been invited or is serving on national or international bodies		
	or committees		
Source of Data	Unit/HR records		
Method of Calculation/Assessment	Count the number of SAMRC researchers contributing to		
	understanding of research findings, guiding policy and service		
	improvement processes, or influencing research funding,		
	through serving as technical advisors, committee members,		
	giving invited (non-conference) presentations at local,		
	Provincial, National and global levels (UN bodies, including		
	but not limited to WHO, UN Office on Drugs & Crime, and		
	World Bank, major funders)		
Means of Verification	Valid proof of membership		
Assumptions	The evidence presented to the auditors is reliable, relevant		
	and valid		
Calculation Type	Cumulative		
Reporting Cycle	Annual		
Desired Performance	To achieve set target for the reporting period		
Indicator Responsibility	President & CEO and CROO		

Indicator Title	5.1.4 Number of conferences, seminars and continuing development points workshops supported by the SAMRC		
Definition	Total number of conferences, seminars and CPD workshops		
	supported by the SAMRC		
Source of Data	Unit/HR records		
Method of Calculation/Assessment	Count the number of SAMRC seminars and CPD workshops		
	which the SAMRC supported financially		
Means of Verification	Proof of payment; evidence of CPD points allocated for		
	attendance and participation		
Assumptions	The evidence presented to the auditors is reliable, relevant		
	and valid		
Calculation Type	Cumulative		
Reporting Cycle	Annual		
Desired Performance	To achieve set target for the reporting period		
Indicator Responsibility	President & CEO and CROO		

ANNEXURES

Annexure A: Consolidated Indicators

Outcome	Outputs	Output Indicator	Annual Target
1.1. To ensure good governance, effective administration and compliance with government regulations	Clean audit opinion	1.1 A clean audit opinion on the SAMRC from the Auditor-General	Clean Audit
1.2 To promote the organisation's administrative efficiency to maximise the funds available for research	Efficient expenditure of government allocated budget	Percentage of the SAMRC total budget spent on administration	20%
2.1. To produce and promote scientific excellence and the reputation of South African health research	Published journal articles, book chapters and books	2.1.1 Number of accepted and published journal articles, book chapters and books by SAMRC affiliated and funded authors	700
	Published journal articles by SAMRC grant-holders	2.1.2 Number of accepted and published journal articles by SAMRC grant-holders with acknowledgement of the SAMRC	180
To provide leadership in the generation of new knowledge in health	Published journal articles with the first or last author	2.2.1 Number of accepted and published journal articles where the first and/or last author is affiliated to the SAMRC	420
To provide funding for the conduct of health research	Research grants awarded	2.3.1 Number of research grants awarded by the SAMRC	150
3.1 To support the development of new or improved innovations aimed at improving health and targeting priority health areas	Innovation projects and platforms funded	3.1.1 Number of new innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	4
		3.1.2 Number of ongoing innovation and technology projects funded by the SAMRC aimed at developing, testing and/or implementing new or improved health solutions	30

3.2	To develop new or improved innovations aimed at improving health in key priority areas	Innovations developed by SAMRC researchers	3.2	Number of innovation disclosures made by the SAMRC intramural research and innovation units and platforms	1
4.	To enhance the long-term sustainability of health research in South Africa by providing funding for the next generation of health	SAMRC bursaries and/or scholarships and/or fellowships provided for MSc, PhD, Postdocs and Early Career Scientists	4.1	Number of awards (scholarships, fellowships and grants) by the SAMRC for MSc, PhD, Postdocs and Early Career Scientists	140
	researchers	Female students and/or Early Career Scientists receiving SAMRC funding	4.2	Number of awards by the SAMRC to female MSc, PhD, Postdocs and Early Career Scientists	100
		African South African citizens and/or permanent residents students receiving SAMRC funding	4.3	Number of awards by the SAMRC to Black South African citizens and permanent resident MSc, PhD, Postdocs and Early Career Scientists classified as African	105
		SAMRC scholarships/ fellowships provided for MSc, PhD, Postdocs and Early Career Scientists at HDIs	4.4	Number of awards by the SAMRC to MSc, PhD, Postdocs and Early Career Scientists from historically disadvantaged institutions (HDIs)	75
		MSc and PhD students graduated or completed	4.5	Number of MSc and PhD students graduated or completed	80
5.	To facilitate the translation of SAMRC research findings into public understanding, policy and	Local or international policies, reports and guidelines that reference SAMRC research	5.1	Number of local or international policies, reports and guidelines that reference SAMRC research	5
	practice	Reports and guidelines produced by SAMRC intramural authors	5.2	Number of reports and guidelines (co)produced by the SAMRC intramural researchers	5
		o, witto intramara authors	5.3	Number of national or international bodies/committees SAMRC employees serve on	50
		SAMRC researchers invited/serving on national and international bodies/committees	5.4	Number of conferences, seminars and continuing development points workshops supported by the SAMRC	10

Annexure B – SAMRC's Materiality and Significance Framework 2022/23

The proposed Materiality and Significance Framework for the SAMRC, in terms of the Treasury Regulation 28.3.1 and the National Treasury Practice Note on Applications under of Section 54 of the Public Finance Management Act (PFMA), is as follows –

Section 50: Fiduciary duties of accounting authorities:

1) The accounting authority for a public entity must –

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(c) on request, disclose to the executive authority responsible for that public entity or the legislature to which the public entity is accountable, all material facts, including those reasonably discoverable, which in any way may influence the decisions or action of the executive authority or that legislature;	Disclose all material facts.	The Board will disclose to the National Department of Health all material facts as requested and all material facts not requested, including those reasonably discoverable, which in any way may influence the decisions or action of the National Department of Health, at the discretion of the Board.

Section 51: General responsibilities of accounting authorities:

1) An accounting authority for a public entity -

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(g) must promptly inform the National Treasury on any new entity which that public entity intends to establish or in the establishment of which it takes the initiative, and allow the National Treasury a reasonable time to submit its decision prior to formal establishment; and	Disclose all material facts timeously.	Full particulars to be disclosed to the Minister of Health for approval after which it is to be presented to Treasury.

Section 54: Information to be submitted by accounting authorities:

2) Before a Public Entity concludes any of the following transactions, the Accounting Authority for the Public Entity must promptly and in writing inform the relevant Treasury of the transaction and submit relevant particulars of the transaction to its Executive Authority for approval of the transaction:

Full particulars to be disclosed	
Full particulars to be disclosed to the Minister of Health for approval and National	
Treasury for noting	
Any asset that would increase or decrease the overall operational functions of the SAMRC, outside of the approved strategic plan and budget.	
or or S.	

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
e) commencement or cessation of a significant business activity; and	Any activity not covered by the mandate / core business of the SAMRC and that exceeds the R15Mil transaction value (based on 2% guidance of total average SAMRC assets, as at 31 March 2021).	Full particulars to be disclosed to the Minister of Health and Minister of Finance (National Treasury) for approval (simultaneous submission).
f) a significant change in the nature or extent of its interest in a significant partnership, trust, unincorporated joint venture or similar arrangement.	Qualifying transactions exceeds R15Mil (based on 2% guidance of total SAMRC assets, as at 31 March 2021)	

Section 55: Annual report and financial statements

- 2) The annual report and financial statements referred to in subsection (1) (d) ("financial statements") must
 - fairly present the state of affairs of the Public Entity, its business, its financial results, its performance against predetermined objectives and its financial position as at the end of the financial year concerned;
 - b) include particulars of—

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(i) any material losses through criminal conduct and any irregular expenditure and fruitless and wasteful expenditure that occurred during the financial year:	All instances	 Report quarterly to the Minister of Health. Report annually in the Annual Financial Statements
(ii) any criminal or disciplinary steps taken as a consequence of such losses or irregular expenditure or fruitless and wasteful expenditure;		
(iii) any losses recovered or written off;		
(iv) any financial assistance received from the state and commitments made by the state on its behalf; and		
(v) any other matters that may be prescribed.	All instances, as prescribed	

Section 56: Assignment of powers and duties by accounting authorities

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
1) The accounting authority for a public entity may— (a) In writing delegate any of the powers entrusted or delegated to the accounting authority in terms of this Ac, to an official in that public entity (b) Instruct an official in that public entity to perform any of the duties assigned to the accounting authority in terms of this Act.	Values excluded from the Delegation of Authority Framework Policy.	Instances that are excluded from the Delegation of Authority Framework Policy.
2) A delegation or instruction to an official in terms of subsection (1)— (c) Is subject to any limitations and conditions the accounting authority may impose; (d) May either be to a specific individual or to the holder of a specific post in the relevant public entity; and (e) Does not divest the accounting authority of the responsibility concerning the exercise of the delegated power or the performance of the assigned duty.	Values excluded from the Delegation of Authority Framework Policy.	Instances that are excluded from the Delegation of Authority Framework Policy.

Treasury Circulars and Guidelines related to Supply Chain Management

- 1) National Department of Health and National Treasury are to be notified of procurement transactions exceeding R15 Million;
- 2) Obtained prior written approval from National Treasury for variation amounts in excess of:
 - a. 20% or R20 Million (including applicable taxes) for construction related orders; and
 - b. 15% or R15 Million (including applicable taxes) for goods / service-related orders

The materiality level mentioned above was calculated using the guidance practice note of the National Treasury. Using these guidance parameters below, the SAMRC materiality level calculation outcomes are as follows:

Element range	% to be applied against R value	Audited Value at 31 March 2021	Calculated Materiality & Significance Value
Total Assets			
(1%-2%)	1.63%	R922 076 642	R15 000 000

The SAMRC materiality and significance value will be R15 Million based on the percentage range of the total asset element and the significant fluctuations in the month-to-month total asset value. This is the most stable element, given the performance statement outcomes associated with the current economic climate challenges.

•

Annexure C: Acronyms

4IR	4 th Industrial Revolution	NIH	National Institutes of Health
AIDS	Acquired Immuno Deficiency	NIMS	National Injury & Mortality Surveillance
	Syndrome		
AU	African Union	NRF	National Research Foundation
BOD	Burden of Disease	NSDA	Negotiated Service Delivery
			Agreement
BRIC	Brazil, Russia, India and China	PhD	Doctor of Philosophy
CANSA	Cancer Association of South Africa	PFMA	Public Finance and Management
			Act
CEO	Chief Executive Officer	PHEF	Public Health Enhancement Fund
CRA	Comparative Risk Assessment	POPI	Protection of Proprietary
			Information
CSIR	Council for Scientific and Industrial	PPIP	Perinatal Problem Identification
	Research		Programme
DHE	Department of Higher Education	Prof	Professor
DR	Doctor	RFA	Request for Application
EE	Employment Equity	SACENDU	South African Community
			Epidemiology Network on Drug Use
EMU	Extramural Research Units	SADC	Southern African Development
			Community
HIV	Human Immunodeficiency Virus	SADHS	South African Demographic Health
			Survey
HR	Human Resources	SAMRC	South African Medical Research
			Council
HRMS	Human Resource Management	SDGs	Sustainable Developments Goals
	System		
HSRC	Human Sciences Research Council	SETI	Science, Engineering, &
			Technology Institution
HVTN	HIV Vaccine Trials Network	SHIP	Strategic Health Innovation
			Partnerships
MDG	Millennium Development Goals	SIR	Self-Initiated Research
MOU	Memorandum of Understanding	SP	Strategic Plan
Mr	Mister	ТВ	Tuberculosis
MTEF	Medium Term Expenditure	UKMRC	United Kingdom Medical Research
	Framework		Council
MTSF	Medium-Term Strategic Framework	UHC	Universal Health Care
NCD	Non-Communicable Disease	UN	United Nations
NDoH	National Department of Health	US	United States
NDP	National Development Plan	USA	United States of America
NHI	National Health Insurance	VAT	Value Added Tax
NHRC	National Health Research	WHO	World Health Organization
	Committee		
NHSP	National Health Scholars		
	Programme		